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ABSTRACT

CHARACTERIZATION OF CUCURBITACIN -INSPIRED ESTRONE ANALOGUES
AS NOVEL INHIBITORS OF HUMAN ATP-BINDING CASSETTE PROTEINS
(ABCB1 AND ABCC1)
JENNIFER KYEREMATENG
2021
ATP-binding cassette (ABC) transporters are a large class of integral membrane
proteins that contribute to key physiological functions in all organisms by
utilizing ATP binding and hydrolysis to transport diverse substrates across
membrane barriers. P-glycoprotein (P-gp/ ABCB1) and Multidrug Resistance
protein 1 (MRP1/ABCC1) are widely reported ABC transporters associated with
multidrug resistance in cancer. Multidrug resistance (MDR) mediated by P-gp and
MRP1 is responsible for treatment failures of many metastatic cancers as a result
of reduced accumulation, bioavailability and diminished potency of anticancer
drugs. Currently, known P-gp and MRP1 inhibitors are limited due to toxicity,
lack of selectivity and low therapeutic benefit which necessitates the investigation
of novel compounds with improved potency and specificity. In this study, we
investigated the inhibition potential of newly synthesized cucurbitacin-inspired
estrone analogs (CIEAs) on P-gp and MRP1 mediated MDR. Utilizing a high
content fluorescence-based transport activity assay initially developed in our lab,
a library of 81 CIEAs were screened to identify inhibitors for P-gp and MRP1
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proteins. The screening assay identified eight P-gp inhibitors using calcein-AM as
a fluorescent reporter. A total of six MRP1 inhibitors were identified using
doxorubicin and calcein red orange as fluorescent reporters. The inhibitory effect
of the identified compounds on P-gp and MRP1 activity were confirmed using
established cell-based functional assays. The identified inhibitors significantly
increased the accumulation of P-gp substrate, calcein-AM and MRP1 substrates,
doxorubicin and calcein red orange. Interestingly, the identified inhibitors
demonstrated selective sensitization of P-gp and MRP1 overexpressing cancer
cell lines towards different anticancer drugs. On the other hand, the identified
inhibitors did not alter protein levels of both P-gp and MRP1. Furthermore, our in
silico and FRET-based spectroscopic studies showed that the inhibitor compounds
directly interact with P-gp and MRP1 proteins. Together, our findings
demonstrated that CIEAs are promising drug candidates for further development
into therapeutic agents against P-gp and MRP1-mediated multidrug resistance in
cancer.
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Chapter 1
Introduction and Background
1.1 Cell Transport and Membrane Transport Proteins
Cell transport is the movement of molecules across biological membranes.
Biological membranes serve as the boundary that separates the cell and other intracellular
organelles from their external environment. These membranes are essential for
intracellular transport by controlling the selective movement of molecules in and out of
cells. Generally, transport of molecules is mediated by specific membrane-associated
proteins, though some transport processes are unassisted by proteins. These membraneassociated proteins are called membrane transport proteins. Membrane transport proteins
play a critical role in regulating several biochemical pathways. Notably, they regulate the
entry of essential substances such as nutrients and ions necessary for metabolism into
organelles thus maintaining cellular homeostasis while also driving the removal of
endogenous waste, toxic substances, metabolites and drugs out of the cell. Consistent
with their crucial role, transporters or transporter related proteins are encoded by
approximately 2000 genes in the human genome [1]. In addition, their importance may be
appreciated from the fact that cells that have defective transport systems have been linked
to several pathological conditions such as metabolic disorders [2, 3] and cancer [4]. Also,
it is not surprising that membrane transporters constitute over 50% of all known drug
targets [5]. Therefore, an extensive knowledge in membrane transport proteins is central
to understanding cell metabolism and function. Membrane transport proteins or
membrane transporters (sometimes used interchangeably) are grouped into four types:
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aquaporins; ion channels; transporters; and ATP-powered pumps [6]. Aquaporins are
water channel proteins that utilize osmotic gradients across membranes to transport
uncharged molecules (water) into and out of cells [7]. Ion channels on the other hand, are
the cell’s electric potential regulator proteins that facilitate the transport of charged
species or ions down their electrochemical gradient across the plasma membrane. While
transporters drive the movement of specific molecules along or against their
concentration gradients by undergoing conformational changes, ATP-powered pumps
transport molecules against their concentration gradients across the plasma membrane
using energy derived from ATP hydrolysis [6]. Membrane transporters can also be
classified as passive or active based on their reliability on cellular energy [6]. Passive
transporters also known as uniporters or facilitative transporters, mediate the energyindependent transport of substrates across the plasma membrane down their concentration
gradient with the aid of special carrier proteins. Active transporters instead, translocate
substrates against or down their concentration gradient in an energy-dependent manner.
However, active transporters that directly depend on energy derived from ATP hydrolysis
to mediate transport are known as primary active transporters. Secondary active
transporters indirectly utilize energy from coupling reactions of the transported molecule
with another molecule along their concentration gradient sometimes driven by H + ions
(proton) or sodium motive forces. The transporter is termed as symporter when the
transported and co-transported molecules are moved in the same direction or antiporter
when both molecules are transported in opposite directions. A diagrammatic presentation
of various mechanisms of transport in biological membranes is shown in Figure 1.1.
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ATP-binding cassette (ABC) transporters, the transporters of interest in this study are
examples of ATP-powered pumps or transport ATPases that include F-, V- and P-type
ATPases and also fall under primary active transporters [8]. An overview of the ATP
transporter family is discussed in the next sections.

Figure 1.1 Membrane transport processes. Diagrammatic representation of the various
mechanisms for the passage/transport of ions and molecules across biological membranes
[9].

1.2 The ABC Transporter Family
ABC transporters constitute a large family of integral transmembrane proteins that
contribute to key physiological processes in all organisms. They are involved in
transporting diverse substrates across membrane barriers using energy derived from ATP
hydrolysis. Substrates of ABC transporters may include small molecules such as ions,
amino acids, polysaccharides, vitamins, lipids, antibiotics, and drugs to even large
molecules like proteins [10]. This transport function leads to physiological processes such

4

as cell growth and development, nutrients translocation, cellular detoxification, lipid
homeostasis, signal transduction and cellular defense [11].
The fundamental protein architecture of a typical ABC transporter consists of two
nucleotide binding domains (NBDs) and two transmembrane domains (TMDs) [12]. The
TMDs are also called membrane spanning domains (MSD) in some literature. The NBDs,
also known as ATP-binding cassette (ABC) from which this family of transporters derive
their name are highly conserved and serve as the motor for energy generation from ATP
binding and hydrolysis. Unlike the NBDs, TMDs are more diverse, and responsible for
substrate recognition and translocation [12]. During transport, substrates may be
recruited either from the inner leaflet (cis-side) or the outer leaflet (trans-side) of the cell
membrane. Subsequently, there is ATP binding and hydrolysis at the cytoplasmic side of
the membrane which then initiates the opening and closing of the TMDs for possible
substrate transport [13]. Based on this cis or trans direction of transport, a given ABC
transporter may function as an importer or exporter. Importers direct substrates from the
trans-side to the cis-side of the membrane. In contrast, ABC exporters translocate
substrates from the cytoplasm to the trans-side, or from the hydrophobic portion of the
lipid bilayer to the trans-side or across the inner and outer parts of the bilayer [13, 14]. In
general, exporters are found in all kingdoms while importers are limited to bacteria and
plants [15, 16]. In bacteria, ABC importers mediate the influx of essential nutrients while
exporters typically efflux drug substrates across the membrane [17]. An interesting
bacterial ABC exporter is LmrA, found in Lactobacillus lactis. LmrA was the first ABCtype transporter discovered to mediate antibiotic resistance in bacteria [18].
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Importers and exporters also differ by the structural organization of their NBD
and TMD domains. The NBD and TMDs in exporters can be combined in various ways
creating a full transporter with varying order of domains. However, for importers, the
TMD and NBD domains are distinct chains and can associate to form a homo- or heterodimeric domains to create a half transporter [14, 17]. Despite these differences, it is
suggested that both transporter types bind ATP and substrates in a similar fashion. In
effect, exporters and importers utilize the same ATP binding and hydrolysis mechanism
to alternate between inward-facing and outward-facing conformations of the transporter
[19, 20]. However, for bacteria importers, substrate translocation requires a high affinity
substrate binding protein (SBP) for delivery to the TMDs [21]. With ongoing studies on
characterization of ABC transporters, more sub-classifications based on structural and
functional diversity have been identified [13, 14, 17]. For instance the Type I and II subgroups have been reported for both ABC exporters and importers. A more recent group,
the Energy-Coupling Factor transporters (ECF) or Type III ABC importers have also
been reported to play specific functions in prokaryotes [22, 23].

1.3 Human ABC Transporter Genes and Associated Diseases
The mammalian species have a total of 56 ABC transporter genes of which 48
genes have been identified in the human genome [10]. The 48 human ABC transporter
genes can be grouped into seven unique subfamilies designated ABCA - ABCG
according to their domain organization and sequence homology. Human ABC
transporters are well known to play pivotal roles in many cellular processes such that
abnormalities in their genes have consequent genetic conditions. At present, 14 ABC

6

transporter genes are related to various genetic disorders. A brief description of the
subfamilies and their associated genetic diseases are discussed in this section.
The ABCA subfamily consists of twelve full transporters and are subdivided into
two groups based on phylogenetic relationships [24]. They are mainly responsible for
lipid transport and homeostasis, regulation of membrane trafficking [25] and retinal
transport [26]. Mutations in the ABCA1 transporter gene results in Tangier disease, a
disorder associated with lipoprotein metabolism [27]; Sjögren syndrome, an autoimmune
disease is due to defects in ABCA7 gene [28] while defects in ABCA4 genes have been
associated with retinal diseases [29].
The ABCB transporters are the only subfamily made up of both half and full
transporters [30]. They are involved in mitochondrial transport, oxidative stress defense
[31], intracellular peptide translocation, antigen processing , DNA repair and
chromosome recombination [32]. Defects in some of these transporter genes (ABCB4
and ABCB11) have been linked to a group of liver diseases known as progressive
familial intrahepatic cholestasis (PFIC) [33]. They are also remarkable for their affinity to
multiple substrates including drugs. The most prominent of this class is
ABCB1(Permeability-glycoprotein) which plays a significant role in multidrug resistance
associated with many tumor cells.
The ABCC subfamily constitute 12 full transporters which are commonly drug
transporters and multidrug resistance proteins (MRPs). This group also contains ‘non
typical’ ABC transporters like the cystic fibrosis transmembrane regulator
(CFTR/ABCC7) which is particularly a cAMP-regulated chloride ion channel [34] and
sulfonylurea receptor (SUR/ABCC8/9), a potassium channel [35, 36]. Aside drug
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transport, the ABCC transporters are also engaged in lipid transport [37], nucleotide and
nucleoside analog transport [38]; glutathione and anion conjugate transport [30]; signal
transduction and chemotaxis; inflammatory responses; cell migration and detoxification
[39]. Some of the known genetic disorders associated with this subfamily are cystic
fibrosis (CF) and Dubin-Johnson syndrome. CF is an autosomal recessive disorder caused
by mutations in CFTR/ABCC7 gene which results in the malfunction of various body
systems such as the respiratory, digestive and endocrine systems [40]. Although several
CFTR gene mutations have been identified, deletion of three bases coding for
phenylalanine at position 508 (F508del) is the most common mutation associated with
CF [40]. The mutation leads to protein misfolding with defective protein trafficking and
post translational modifications. Dubin-Johnson syndrome results from mutations in
ABCC2/MRP2 or canalicular multispecific organic anion transporter (cMOAT) gene.
Such mutations include deletions of Arg1392 and Met1393, causing abnormalities in
protein maturation and trafficking [41]. ABCC2 is an organic anion transporter localized
mostly to canalicular membranes of hepatocytes where it is actively involved in biliary
transport of endogenous and exogenous compounds hence the disease is characterized by
a bile-associated liver disorder [41][42]. Defects in ABCC6 genes have also been
reported to cause pseudoxanthoma elasticum (PXE), a connective tissue disorder [43].
Consistent with their drug transport function, members of this subfamily (ABCC1,
ABCC2, ABCC3, ABCC4, ABCC6, ABCC10 and ABCC11) are multidrug resistance
proteins and are highly expressed in a variety of cancers where they contribute to
chemoresistance and disease progression [44]. The most well studied among this group is
ABCC1/ MRP1.
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The ABCD subfamily genes consist of four half transporters mainly involved in
peroxisomal transport of very long chain fatty acids (VLCFA) [45]. An exception to this
function is the ABCD4 transporter, which is localized in lysosomes and endoplasmic
reticulum (ER) and involved in intracellular transport of Vitamin B 12 [46]. The effects of
ABCD gene mutations are peroxisomal disorders such as X-linked adrenoleukodystrophy
(ABCD1), which is caused by toxic concentrations of VLCFA. Mutations in ABCD3
have also been linked to spleen disorders (hepatosplenomegaly) while defects in ABCD4
gene are associated with abnormal Vitamin B 12 metabolic disorders [46, 47]. The ABCE
and ABCF subfamilies though called ABC transporters, do not act as transporters due to
the absence of TMD in their structure. They are rather thought to play significant roles in
cell division and regulation of translation initiation factors [48-50].
The last group of the ABC transporters, the ABCG subfamily members are lipid
and cholesterol transporters. Mutations in their genes are associated with toxic
intracellular amounts of cholesterol in liver and intestines [51]. ABCG2 or breast cancer
resistant protein (BCRP) is the most-studied member of this subfamily and function as a
drug efflux pump that confers drug resistance in many cancer cells. It is also known to
play a vital role in renal uric acid transport. Therefore mutations in ABCG2 gene result in
gout, a renal disease characterized by excess plasma accumulation of urate crystals [52].
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Figure 1.2 Phylogenetic tree showing human ABC transporter gene family. The root
‘ABC’ is omitted from the figure to simplify it. Thus, the correct gene name for ‘B1’ is
ABCB1, for ‘B4’ is ABCB4, and so forth [6].

1.3 Structure, Organization and Mechanistic function of ABC Transporters
A typical eukaryotic ABC transporter consists of a single polypeptide organized into
four functional units or domains that can be found associated in the membrane. The
functional units consisting of two nucleotide binding domains (NBDs) and two
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transmembrane domains (TMDs) make up the fundamental architecture of the
transporter. The NBDs belong to a group of nucleotide binding proteins (NTP) known as
P-loop NTPases that require the catalytic activity of magnesium ions to function [53].
The NBDs are also hydrophilic in nature and located at the cytoplasmic side of the
membrane [54]. Each NBD contains two subdomains (Figure 1.3B): a catalytic or RecAlike domain and a helical domain.

Figure 1.3 Schematic representation of NBDs and coupling helices. (A) Side view (from
the membrane plane) of an ABC transporter. NBDs (blue and green) are attached to the
TMDs (gray) via so-called coupling helices (red) present in loops of the TMDs. ATP
binding and hydrolysis cause rearrangements in the NBDs, which are propagated to the
TMDs via the coupling helices. (B) Top view (along an axis perpendicular to the
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membrane) of the NBDs and the coupling helices from the TMDs. (C) The relative
positions of sequence motifs in NBDs [13]

The domains are evolutionary highly conserved with various sequence motifs performing
specific functions for ATP catalysis during substrate transport [13, 14, 54, 55]. The
RecA-like domain starts from the N-terminal with the A-loop motif (Figure 1.3C). The
A-loop has a conserved aromatic residue (mainly tyrosine) responsible for assembling the
adenine ring of ATP for better anchorage during ATP binding. Next, the Walker A (Ploop) motif (GXXGXGK(S/T)) which contains highly conserved lysine residues is the
part of the NBD that interacts with the phosphate groups of ATP. The Q-loop follows the
Walker A motif. This has highly conserved glutamine residues and serves as the active
site for ATP hydrolysis and the main point of connection with the TMDs. The C or ABC
motif begins the helical domain. The consensus sequence of this motif (LSGGQ) is the
signature feature of all ABC transporters and it functions to position the helix for
interaction with the phosphate groups of ATP. The Walker B (φφφφDE, φ = hydrophobic
residue) motif with its conserved glutamate residue acts as a polarizing base for ATP
against attack by water molecules. The D-loop motif (SALD) comes next to the Walker B
and helps to create the platform for ATP hydrolysis. The H-loop or H-switch ends the
NBD at the C terminus. It has a highly conserved histidine residue responsible for
essential interaction with other motifs at the catalytic site.
Unlike the NBDs, the TMDs are highly hydrophobic and depending on the
transporter subfamily, each TMD may contain 6-11 (usually 6 for eukaryotic ABC
exporters) transmembrane spanning segments [56]. Thus, for a full human ABC
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transporter, the TMD may contain a total of 12 transmembrane spanning α-helix
segments. Largely, the TMDs show no substantial sequence similarity and are thus
structurally heterogenous though they may share similar network within the same
transporter subfamily. The structural dissimilarity thereof for TMDs is suggested to be
responsible for the broad specificity of ABC transporters to a variety of substrates. This is
especially evident for the multidrug transporter P-glycoprotein (P-gp) which has been
termed to exhibit ‘polyspecificity’ to a number of substrates [57]. In addition,
experiments done on human P-gp and multidrug exporter Sav1866 from Staphylococcus
aureus revealed that the TMD helical segments are arranged in a manner that creates a
substrate translocation pathway extending from the cytoplasm towards the membrane
exterior [14, 58].
Under normal cell function, ABC transporters transverse substrates across the
membrane against a concentration gradient using energy derived from ATP binding and
hydrolysis. For exporters, this transport process is done in a unidirectional manner. This
means that the transporter functional domains must operate in a complementary manner
for the transport to occur. The transduction of conformational changes between the NBDs
and TMDs is said to be crucial for this mechanistic transport process. Despite the NBDTMD dissimilarities, their domain interactions are made possible through coupling
helices identified in the TMDs [19]. The coupling helix describes a brief α-helical motif
present at one of the cytoplasmic projections of the TMD that fits into a pocket of a NDB.
The coupling interaction between the TMDs and NBDs in this manner is necessary for
transmitting conformational changes from the catalytic site of the NBDs to the TMDs.
The pocket of the NBD where this coupling interaction occurs is the border between the
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helical and RecA-like subdomains where the Q-loop motif is located. The interface of the
two subdomains plus the conserved glutamine in the Q-loop motif facilitates this
interaction. Moreover, crystallography studies on some ABC transporters also suggest
that the dimerization of NBDs in a ‘sandwich’ fashion is central to the conformational
changes in TMDs [59]. Consequently, more studies have proposed several mechanistic
transport models such as the ATP- switch [60], alternating catalytic site [61], constant
contact [62] and the reciprocating twin-channel [63].
The ATP- switch model proposed by Higgins and Linton is the most commonly
cited mechanistic model for ABC proteins [60]. This model describes the switching of
two conformations of the NBDs alongside ATP binding and hydrolysis and the resulting
conformational changes induction in the TMDs. With respect to substrate translocation in
ABC exporters, the transport cycle is triggered by binding of the substrate to the TMDs.
The presumable binding of substrate to the high-affinity TMDs site promotes the
transformation of the open NBD dimer (low ATP affinity) conformation to the closed
dimer (high ATP affinity) conformation. In essence, the binding of substrate favors the
closed dimer conformation by lowering the activation energy of the process and also
increasing the NBDs affinity for ATP. Binding of two ATP molecules at the interface of
the NBDs and the closed dimer formation induce non-covalent conformational changes in
the TMDs. The changes in the conformation of the TMDs reduce the binding affinity of
the substrate allowing it to be released. ATP is subsequently hydrolyzed with release of
ADP, and inorganic phosphate. The NBDs are dissociated and finally reset to their
physiological ground state or non-dimeric form to reinitiate another transport cycle. The
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substrate-induced conformational changes consistent with the ATP-switch model have
been reported in transport studies for P-gp [64, 65] and MRP 1 [66].

1.5 Human ABC Transporters and Multidrug Resistance in Cancer
The World Health Organization (WHO; www.who.int) reports cancer as the
second leading cause of mortality worldwide after heart disease, accounting for ~ 9.6
million deaths or 1 in every 6 deaths in 2018. The number of new cancer cases reported
in 2018 was ~ 18.1 million and by 2030, this number is expected to increase by more
than 80% annually [67]. Current cancer treatment modalities include chemotherapy,
radiotherapy, immunotherapy and surgery though chemotherapy remains the traditional
approach for managing cancer [68]. Notwithstanding the substantial progress made in
chemotherapy, survival rates in many cancer types still remain significantly low
unfortunately due to multidrug resistance (MDR) mechanisms. MDR is believed to be
responsible for treatment failure in more than 90% of patients with metastatic cancers
[69]. The multidrug resistance term describes the ability of cancer cells to develop cross
resistance to a number of structurally and pharmacologically unrelated chemotherapeutic
agents [70] . The underlying mechanisms (Figure 1.4) identified to cause MDR include
increased drug efflux, reduced drug influx, drug target alteration, deactivation of drug
metabolic and apoptotic mechanisms as well as mutations among others. The most
frequent and the widely studied mechanism is increased drug efflux mediated by ABC
transporters [71]. Amongst the ABC efflux pumps identified as drug transporters, Pglycoprotein/ABCB1, MRP1/ABCC1 and BCRP/ABCG2 have gained more attention in
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MDR related cancers. This work focuses on multidrug resistance mediated by Pglycoprotein and MRP1.

Figure 1.4. Mechanisms of multidrug resistance in cancer [72].
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1.6 Permeability Glycoprotein (P-gp/ABCB1)
P-gp is the first to be discovered in the human ABC transporter family and the
most extensively characterized ABC protein. P-gp protein was originally identified
overexpressed in tumor cells of Chinese hamster selected for multidrug resistance and
was later cloned in mouse and humans [73]. The fundamental core of P-gp consists of
two NBDs and two TMDs as shown in Figure 1.5. The NBD and TMD domains
organization for substrate translocation using energy derived from ATP binding and
hydrolysis depicted by P-gp is characteristically the same for the family of ABC efflux
transporters. The P-gp gene (mdr1) is encoded with 1280 amino acids giving a 170 kDa
protein separated into two homologous halves located at the N- and C- terminals [74, 75].
Each homologous half contains a NBD accompanied by a TMD with six transmembrane
spanning helices. A flexible linker peptide or region of approximately 75 amino acids
connects the two halves. The linker region is responsible for proper interaction of the two
halves and also couple ATPase activity for drug binding and efficient P-gp transport
function [74, 75].

Figure 1.5 Typical structural architecture of P-gp transporter. Adapted from [76]
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The diversity of substrates transported by P-gp may include neutral or positively
charged compounds but mainly amphipathic or hydrophobic compounds that can
appreciably penetrate the plasma membrane into tissues [77]. Many of the substrates
include various anticancer drugs such as vinca alkaloids, anthracyclines,
epipodophyllotoxins and clinically important therapeutics like HIV protease inhibitors,
cardiac glycosides, immunosuppressive agents, antibiotics and corticoids [77].
Considering the unique ability of P-gp to transport a variety of chemically diverse
compounds, the molecular basis behind its broad substrate and polyspecificity is still not
clear. Nonetheless, critical studies of P-gp structure, the nature of its TMDs and the drug
binding sites have shed light onto its unique properties. High-resolution crystal structures
of mouse P-gp (87% sequence similarity to human P-gp) by Aller et al revealed that P-gp
can differentiate between stereoisomeric compounds and consequently generate distinct
binding spots with varied orientational chemistries for multiple substrates [57].
Furthermore, an inward facing conformation of the TMDs facilitates the formation of an
internal cavity (of volume ∼6,000 Å3 ) which is large enough to hold at least two
different substrates concurrently [78]. Additionally, the TMDs conformations promote
different topologies of the drug binding pocket which is characterized by highly
conserved residues [79]. The flexibility of the drug binding pocket topologies in addition
to the highly conserved residues in the pocket may account for the substrate
polyspecificity nature of P-gp. The ability of P-gp to transport diverse molecules
especially hydrophobic substrates can be explained by the abundance of hydrophobic and
aromatic residues in the drug binding pocket that permit the recruitment and partitioning
of hydrophobic substrates into the lipid bilayer of the membrane. During its transport
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activity, P-gp is able to identify substrates from the bilayer or inner leaflet of the
membrane and ‘flip’ or extrude them into the outer leaflet of the membrane or
extracellular environment. Mutational and photolabeling experiments of P-gp have also
confirmed the contribution of the TMDs to substrate specificity [74, 80]. In short, the
TMDs, the large internal cavity, the drug binding pockets and conformational changes
allow P-gp to scan, accommodate and bind diverse substrates and subsequently extrude
them out of the cell.

The distribution of P-gp in normal physiology is important for major cellular
functions like lipid homeostasis, metabolite excretion, among others. P-gp is localized to
apical membranes of specialized epithelial cells of the intestines, kidney, liver and
pancreas where major metabolites excretion occur [81]. P-gp is also expressed in
endothelial cells of luminal blood barriers of sensitive tissues such as the brain, nerves,
testis and the placenta and thus plays an important physiological role in tissue defense
against xenobiotics [82]. Consistent to the essential role played by P-gp in sensitive
tissues, the pathological effects of cytotoxic drugs in the brain, testes and placenta have
been demonstrated in numerous experimental models. An important example is the
increase in fetal sensitivity to teratogenic substrates among other cytotoxins and
subsequent neonatal abnormalities often reported in the placenta of P-gp knockout mice
[83, 84]. On the other hand, overexpression of P-gp in brain and nerve tissues in diseased
conditions may impede pharmacological behavior of selective therapeutics such as
antiepileptics, antiemetics and antidiarrheals targeting the brain or central nervous system
(CNS) [85].
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Given its crucial physiological functions in normal cells, P-gp overexpression in
tumor cells is a crucial index for drug pharmacokinetics such as the absorption,
distribution, metabolism and excretion (ADME) of orally administered chemotherapeutic
drugs. Reduced intracellular drug bioavailability is a major obstacle to successful
chemotherapy. Although not always the case, a viable correlation between elevated levels
of P-gp, tumor insensitivity and patient response or survival rates have been established
in some hematological malignancies (leukemias), neuroblastoma, colon, adrenal, bladder,
breast and endometrial carcinomas [86-89].

1.7 Multidrug Resistance Protein 1 (MRP1/ABCC1)
Multidrug resistance protein 1 (MRP1) is the second known ABC transporter
implicated in clinical multidrug resistance. MRP1 was initially identified for its role in
conferring resistance to a number of anticancer drugs in a doxorubicin-selected lung
cancer cell line (NCI-H69) which was not overexpressing P-gp [90]. The 190 kDa MRP1
(encoded with 1531 amino acids) has an extra membrane spanning domain (MSD0)
(Figure 1.6) with five transmembrane helices at the N-terminal region in addition to the
typical four core domains (two NBDs and two MSDs) observed in P-gp and other ABC
proteins [91]. The twelve transmembrane helices in the MSD1 and MSD2 (as shown in
Figure 1.6) form the substrate translocation pore through which solutes are transported,
however, the function of the MSD0 in relation to MRP1 transport activity is not well
understood [92]. MRP1 transport is governed by ATP binding and hydrolysis with
conformational change transduction from the NBDs to the MSDs. Transport is initiated
by the binding of substrate and ATP to the two NBDs, which is then accompanied by a
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head-to-tail orientation and sandwich dimer formation of the NBDs. ATP-binding and
dimerization of the NBDs are facilitated by three characteristic sequence motifs in the
NBDs: the Walker A, Walker B and the signature C motifs [63, 92] . Interestingly, ATP
binding to the NBDs is asymmetrical, generating two sites namely: the ‘degenerate’ and
‘consensus’ sites [63, 93]. Whereas the NBD1 has a low ATPase activity with higher
affinity for ATP binding at the degenerate site, the NBD2 on the other hand, has a higher
ATP hydrolysis ability at the consensus site [93]. The asymmetric catalytic activity at the
NBDs is a characteristic feature of MRP1 and the other members of its subfamily but not
observed in P-gp.

Figure 1.6 Topology and domain structure of MRP1 [94].

The substrates of MRP1 are mostly organic anions from endogenous or
exogenous sources several of which are conjugated to glutathione, glucuronic acid or
sulfates [95]. Especially, the transmembranes, (TMs) 10, 11, 16 and 17 in MRP1 are
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remarkably amphipathic and thus contain predominantly polar amino acids. Conversely,
corresponding TMs (5, 6, 11 and 12) of P-gp are less amphipathic accounting for the
ability of P-gp to transport mostly hydrophobic substrates but not hydrophilic organic
anionic compounds [92]. Furthermore, the TMDs in MRP1 have comparably large
number of ionizable amino acids. Evidence suggests that the TMDs residues have
hydrogen-bonding abilities that favor intrahelical or interhelical ion pair interactions with
hydrophilic organic anions [96]. MRP1 also transports a broad range of antineoplastic
agents such as vinca alkaloids, epipodophyllotoxins, methotrexate and camptothecins
many of which are also substrates of P-gp. Many clinically important therapeutics e.g.
antibiotics, antivirals, antidepressants, statins and metal oxyanions are also substrates of
MRP1 [94, 97]. Additionally, MRP1 is the primary transporter of endogenous anionic
substrates such as glutathione (GSH), cobalamin, bilirubin, estradiol glucuronide
(E217βG) and cysteinyl leukotriene (LTC4) [98-100]. The ATP-dependent transport of
the antioxidant GSH and the pro-inflammatory molecule LTC 4, presents MRP1 as an
essential mediator in cellular redox homeostasis, cell differentiation, proliferation and
immunological reactions. Therefore, it is not surprising that MRP1is associated with the
etiology of many metabolic, cardiovascular, neurological, immunological and tumor
related diseases in humans [92].
MRP1 is normally distributed in tissues including the lung, gastrointestinal tract,
cardiac, liver, pancreas, adrenal cortex, skin and skeletal muscle but unlike P-gp, MRP1
is localized to basolateral membranes of polarized epithelia [101]. However, like P-gp,
MRP1 is also expressed in pharmacological sensitive barriers and therefore exerts
chemoprotective functions in these tissues. In fact, a study demonstrated that co-
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expression of both MRP1 and P-gp in sensitive tissue compartments is essential for
cumulative tissue protection. In mice genetically lacking both P-gp (mdr1a/1b) and
MRP1 (mrp1) genes, it was reported that a substantial fold increase in toxicity of
chemotherapeutic drugs, vincristine and etoposide was observed in embryonic fibroblasts
as compared to drug doses in only P-gp lacking mice [102].
Similarly, MRP1 expression in many drug-resistant malignant and non-malignant
diseases is a major factor to successful clinical outcomes. Especially in malignant
diseases, MRP1 expression is contributive indicator for drug absorption and disposition.
An unfavorable pharmacokinetic response leads to poor clinical outcome in many
patients particularly with non-small lung cancer (NSLC), acute myeloid leukemia,
(AML), and breast cancer [103-105]. In addition, high MRP1 expression levels have been
linked to aggressive and multidrug resistance traits in neuroblastoma [106], and thus
MRP1 is a key individual prognostic indicator of childhood neuroblastoma
It can be safe to say that both P-gp and MRP1 are key contributors to clinical
multidrug resistance in cancer due to their distribution, expression and the wide diversity
of xenobiotic substrates transported by them. To date, several attempts to forestall MDR
mediated by these ABC proteins remains a challenge. The prevailing challenges facing
MDR circumvention are discussed in the next section.

1.8 Current strategies for P-gp and MRP1 inhibition
The rationale to circumvent MDR is to introduce compounds that will inhibit the
activity of ABC drug efflux pumps and thus re-sensitize drug resistant tumors to respond
to chemotherapeutic agents. The objective is to enhance the intracellular accumulation of

23

the chemotherapeutic drug and improve the overall clinical outcome in many cancers.
Although several laboratory or preclinical studies geared toward inhibiting these ABC
proteins have shown promising outcomes, unfortunately transition and replication in
clinical settings have not been favorable. The possible reason(s) accounting for the poor
outcomes have been discussed in literature [107, 108], however, a brief summary of
selected inhibitor compounds against P-gp and MRP1 and their limitations are discussed
here.

1.8.1 First generation P-gp inhibitors
Over the last four decades, an extensive search for compounds against P-gp, have
led to three pharmacological generations of P-gp inhibitors [109]. The first generation
inhibitors were introduced by taking advantage of the polyspecificity nature of P-gp and
included drugs already in use for other therapeutic applications such as verapamil,
felodipine, nifedipine, chlorpromazine, quinine and cyclosporin A. Verapamil, a calcium
channel blocker showed effective MDR reversing ability, however, its use in clinical
trials was terminated as a result of serious cardiotoxicity. [110]. Also, verapamil required
high plasma concentrations in order to achieve a significant P-gp blocking activity [111,
112]. Likewise, cyclosporin A, an immunosuppressive agent did not improve treatment
outcomes in a randomized phase II clinical trials of patients with relapsing acute myeloid
leukemia in combination therapy with etoposide and mitoxantrone due to increased
toxicity [113, 114]. The apparent challenge that faced this generation of inhibitors was
their low specificity to P-gp. The reason being that they were not specifically developed
for P-gp inhibition. Also, many of them emerged as substrates of P-gp and acted

24

competitively with other chemotherapeutic substrates. Coupled with the low specificity
and different pharmacokinetic effects of these inhibitors, high doses were required for
their potency hence the undesirable toxic effects observed.

1.8.2 Second generation P-gp inhibitors
Owing to the limitations of the first generation compounds, the second generation
inhibitors were developed as derivatives from the first generation compounds through
chemical optimizations. The second generation inhibitors lacked the original
pharmacological activity of their parent compounds but were still hindered by low
specificity, toxicity and pharmacokinetic effects. This generation of inhibitors include
dexverapamil, emopamil, and PSC-833 [115]. The prominent among them, PSC-833
(valspodar), is an analogue of cyclosporin A with no immunosuppressive activity. Studies
have indicated that PSC-833, though was more specific and less toxic than its parent
compound, interfered with the activity of CYP3A4 which belongs to the family of drug
metabolizing enzymes, cytochrome P450 3A4, when used in combination with anticancer
drugs [116, 117]. Since the metabolism and excretion of most drugs including anticancer
drugs depend on CYP3A4 activity, inhibition of CYP3A4 by these inhibitors likely
affected anticancer drugs in two ways: i) reduced the therapeutic effect of the drug due to
decreased metabolism by CYP3A4 (ii) increased drug exposure or plasma drug
concentration with resultant toxic effects due to decreased drug clearance. To overcome
these challenges, a low cytotoxic drug dosage was required in order to limit
pharmacokinetic interactions and ensure patient safety. The low cytotoxic dosage was
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insufficient to produce the desired therapeutic benefit and therefore rendered this
generation of inhibitors clinically non-beneficial [117].

1.8.3 Third generation P-gp inhibitors
To solve the problems of non-specificity, low potency and toxicity, the third
generation inhibitor compounds were designed using combinatorial chemistry and
structural-activity relationship (SAR) approaches. Notable among these compounds that
were able to get to the clinical trial stages include tariquidar (XR9576), zosuquidar
(LY335979), and laniquidar (R101933) [118]. A Phase I study with tariquidar in
combination with anticancer drug vinorelbine or P-gp fluorescent substrate rhodamine
showed tariquidar to be a potent P-gp inhibitor with no considerable toxicity or
pharmacokinetic effects [119]. However, in another study where tariquidar was combined
with docetaxel in patients with lung, ovarian or cervical cancers, tariquidar was observed
to have no clinical advantage on patients even though no intolerable pharmacokinetic
interactions were recorded [120]. Similarly, in a randomized placebo-controlled doubleblind study of patients with newly diagnosed AML or high-risk myelodysplastic
syndrome, zosuquidar showed no effect on the overall survival or remission rate of
patients [121]. The possible reasons for this roadblock has been attributed to the
following: patients selection not based on high P-gp expression, presence of other efflux
mechanisms or not accounting for them and possible occurrence of transporter
polymorphisms resulting in interpatient variability among others [107].
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1.8.4 MRP1 Inhibitors
Compared to P-gp, the search for MRP1 inhibitors is still in early stages since
MRP1 was discovered years after P-gp. Additionally, the preference of MRP1 for organic
anionic substrates have slowed down the search for MRP1-specific inhibitors. The
selected inhibitor should possibly have anionic properties to possess a high affinity
towards MRP1 for efficient inhibition. There is also the problem of inadequate
intracellular drug accumulation (of the inhibitor) to cause the desired therapeutic effect
due to inability of anionic compounds to effectively penetrate into cells. Nonetheless,
there has been some progress made with the search for small molecule MRP1 inhibitors
such as MK571, probenecid, sulfinpyrazone, benzbromarone, and indomethacin. MK571,
the popular MRP1 inhibitor is an LTC4 analogue primarily developed as a leukotriene D4
receptor antagonist for the treatment of asthma [94]. It was identified as a competitive
inhibitor of LTC4 (and other organic anionic substrates of MRP1) and also reversed drug
(particularly vincristine) resistance in MRP1 overexpressing cells [122]. However,
MK571 lacks specificity as it also inhibits other organic anion uptake systems like
organic anion transporting polypeptide or solute carrier organic anion transporters
(OATP1B3/SLCO1B3) and other proteins in the ABCC family [94, 123].
Sulfinpyrazone, benzbromarone and probenecid have also been reported as organic anion
uptake transporter inhibitors [77].
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Some P-gp inhibitors have been identified to modulate the function of MRP1.
Among them, cyclosporin A and its analogue PSC 833 are reportedly known to inhibit
MRP1 though with poor specificity [98]. Tyrosine kinase inhibitors (TKIs) like imatinib,
ibrutinib, and AG1393 have also shown inhibitory activity on MRP1 [124-126]. Zheng at
el, in a previous study demonstrated that vandetanib, a commercial orally administered
drug inhibiting multiple receptor tyrosine kinases has dual inhibition on both MRP1 and
BCRP- mediated drug resistance in a dose-dependent manner [125]. A recent study also
found GSK1904529A, a potent inhibitor of insulin-like growth factor-I receptor (IGF-IR)
tyrosine kinase, to inhibit the function of MRP1 by increasing the sensitivity of MRP1
overexpressing MDR cells and also enhancing the efficacy of MRP1 anticancer
substrates [127]. Novel strategies using nanoparticle drug delivery systems have also
shown promise in MRP1 inhibition [128, 129]. Notwithstanding, the data accumulated on
current MRP1 inhibitors, their limitations have not positioned them as potential
candidates for clinical trials evaluation. Some common P-gp and MRP1 inhibitors are
shown in Table1.1
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Table 1.1 Some common P-gp and MRP1 inhibitors
P-gp Inhibitors

MRP1 inhibitors

First generation

Second generation

Third generation

Verapamil

Dexverapamil

Reserpine

Gallopamil PSC

Tariquidar
(XR9576)
KR30031

Progesterone

833 (Valspodar)

Tamoxifen

VX-710 (Biricodar)

Felodipine

MS-209 GF

Nifedipine

120918 (Elacridar)

Erythromycin

Reversin 121

Flufenazine

Reversin 125

Cyclopropyldiben
-zosuberane
Zosuquidar
(LY335979)
Laniquidar
(R101933)
Substituted
diarylimidazole
ONT-093

MK571
Probenecid
Indomethacin
Imatinib
Ibrutinib
AG1393

Diltiazem
Chlorpromazine
Quinidine
Cyclosporin A

1.9 Natural Products as potential source of drug strategies against multidrug
resistance in cancer
Though both P-gp and MRP1 inhibitors have failed to show success in therapeutic
and clinical settings to date, utilizing modulators (inhibitors) to block ABC transportermediated activity is still the cheapest, simplest and direct way for circumventing
multidrug resistance. Therefore, it is prudent that the search for inhibitors is not
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abandoned, but rather extended to include a manifold alternative strategies. Current
alternative strategies used to target MDR include gene regulation technologies such as
antisense oligonucleotides, RNA interference, transcriptional regulation; nanomedicine
technologies, or a combination of both technologies, and the application of natural
products [130, 131]. Amongst them, natural products application has garnered more
attention in the search for MDR inhibitors. Historically, natural products and their drug
derivatives are sources of many therapeutic agents for treatment of approximately 87%
classified human diseases [132]. Furthermore, drugs derived from natural products are
among the top 35 ethical drugs sold globally [133]. A study has shown that more than
half of prescription drugs in the United States most of which fall under anti-allergic,
analgesics and cardiovascular agents are obtained from natural products [134]. The
extensive structural and chemical diversity of natural products make them suitable for
semi- and total synthetic modifications. In addition, natural products are highly potent,
safe and tolerable to use with minimal inherent toxicity compared to synthetically derived
drugs [134]. Therefore, natural products are significant sources of new pharmacological
leads in the drug discovery and development process.
In the face of the challenges encountered by current P-gp and MRP1 inhibitors,
compounds from natural origin will be more desirable for developing drug strategies to
overcome multidrug resistance due to the advantages already mentioned. Indeed, some
studies have referred to promising natural products-derived compounds as the fourth
generation inhibitors. Natural products such as alkaloids, coumarins, curcumin,
flavonoids, and terpenoids have already been reported to have inhibitory and considerable
MDR reversing activities in many cancer cell lines with minimal toxicity. Notably
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flavonoids, a group of plant-derived phenolic compounds were found to significantly
enhance the accumulation of P-gp substrate, daunomycin in vitro and also conferred
absent to moderate pharmacokinetic effect on doxorubicin, cyclosporin A and paclitaxel
in an in vivo study [135]. In a study screening dietary flavonoids, quercetin and rutin
were found to inhibit P-gp function and also reduced paclitaxel resistance in P-gp
overexpressing human KB CHR 8-5 carcinoma multidrug resistance cell lines [136].
Coumarins and their derivatives have also shown to reverse P-gp resistance and increased
chemotherapeutic drug bioavailability in cancer cells [137, 138]. Similarly,
tetrahydrocurcumin (THC), the main metabolite of curcumin (derived from turmeric)
inhibited the function of P-gp, MRP1 and BCRP and also re-sensitized their multidrug
resistance cell lines to chemotherapeutic drugs [139].

Cucurbitacins are the main natural product of interest in this work. The origin,
structure and potential of cucurbitacins as therapeutic candidates for attenuating
multidrug resistance in cancer are discussed in the next section.

1.9.1 Cucurbitacins – origin and structure
Cucurbitacins are a class of diverse compounds made up of highly oxidized
tetracyclic triterpenoids and present in different species of the plant family Cucurbitaceae
[140]. They are predominantly found in plants such as cucumber, honeydew melons,
Crenshaw melon, pumpkin, cantaloupe, squash, pumpkin, angled gourd, bottle gourd,
watermelon and colocynth. [141]. They are also known to be responsible for the bitter
taste in these plants. The chemical structure of cucurbitacin includes a steroidal carbon
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skeleton (Figure 1.7) or basic triterpenoid (carbon-30 compound with IUPAC name
19(10–9ß)-abeo-5α-lanostanes) built from six isoprene units with oxygen substitutions at
different positions [140, 141].

Figure 1.7 Cucurbitacin skeleton [141].

Cucurbitacins are classified into twelve types designated A to T. The diversity of the
different cucurbitacin classes is based on the positions of substituent molecules
(hydroxylated, unsaturated, keto, glycosyl and acyl groups) attached to them. [142]. As
reported by Miro, cucurbitacins A, B,C, D, E, F, I, O and Q contain unsaturated
substitutions at carbon position 23 (C-23). On the other hand, cucurbitacins G, H, J and K
are typically unsubstituted except for a hydroxyl group on C-24. In general, the basic
structure of cucurbitacins is characterized by a gem-dimethyl group at C-4 and an
isopropyl group at C-24. There is also presence of methyl groups at positions C-9,C13,C-14, and C-20. Cucurbitacins basic structure is also defined by unsaturation at C-5
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[140]. Cucurbitacins can also be identified based on whether they are naturally occurring
or products from enzymatic reactions. [140]. Cucurbitacins B and E are believed to be the
naturally occurring cucurbitacins in plants from which the other types are generated
through metabolic processes. For instance, cucurbitacins A, C, D, F, G, and H, are
products from metabolism of cucurbitacin B while cucurbitacins I, J, K, and L are
derived from metabolism of cucurbitacin E [140]. Furthermore, cucurbitacins B and D
could be converted to their reduced forms, 23,24-dihydrocucurbitacin B and 23,24dihydrocucurbitacin D, respectively.

1.9.2 Cucurbitacins Antitumor Activities
Cucurbitacins (Cucs) were earlier used for treatment of liver diseases such as
jaundice, cirrhosis and hepatitis in folk medicine due to their natural hepatoprotective
properties [142]. Besides this property, cucurbitacins also possess other important
pharmacological traits and were thus utilized as purgatives, anti-inflammatory and
antimicrobial agents [143]. The antitumor activity of cucurbitacins was discovered more
than 50 years ago, however, due to serious toxic effects in humans, their usage
subsequently diminished [144]. Fortunately, developments leading to in vitro anticancer
drug screening on 60 human tumor cell lines by the National Cancer Institute (NCI-60)
[140] restored their potential as prospective source of anticancer compound candidates.
To understand the biological mechanism of cucurbitacins, recently, more research have
focused on their cytotoxic and antitumor activities.
Cucurbitacins B, D, E and I are amongst the widely explored cucurbitacins in
cancer studies [145]. Accumulated data have shown evidence of their remarkable
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antitumor activities in various cancer profiles both in vitro and in vivo. Cucurbitacin B
particularly, has exhibited potent cytotoxic and antitumor activities in more than 100
tumor panels e.g. breast, colon, leukemia and lung cancers [146, 147]. The antitumor
activity of cucurbitacin B has been attributed to its ability to induce various phases of cell
cycle arrest and apoptosis by modulating several signaling pathways in tumor cells. For
instance, cucurbitacin B induced G2 arrest and caspase-dependent apoptosis in human
colon adenocarcinoma SW480 cells in a reactive oxidative species (ROS)-dependent
manner while activating caspases and suppressing the expression of cyclin B1 and
cdc25C proteins [148]. Cucurbitacin B has also displayed in vitro and in vivo
antiproliferative and apoptotic activities through JAK/STAT inhibition mechanism in
human pancreatic cancer cells [149]. Treatment of breast cancer cell lines (MCF-7 and
MDA-MB-231) with cucurbitacins B and E glucosides extracted from the leaves of
Citrullus colocynthis inhibited tumor growth through cell cycle arrest and apoptosis
[150].
Similarly, a plethora of reports have so far demonstrated cucurbitacin D has
inhibitory effect on leukemic, hepatic, colon, lung, breast and central nervous system
carcinoma cell lines [140]. In a recent study, cucurbitacin D suppressed metastasis in
prostate cancer cells via a glucose regulation mechanism [151]. Cucurbitacin E in a
similar study was reported to play a significant role in microtubule skeletal elements
(actin and vimentin) disruption, which are responsible for tumor aggression in prostrate
carcinoma [145, 152]. In addition, a combination of cucurbitacin E with doxorubicin
treatment enhanced the chemotherapeutic and collective antitumorigenic effect both in
vitro and in vivo in gastric cancer [153]. The induction of cell cycle arrest and apoptosis
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through inhibiting the PI3KAkt signaling pathway in multiple cancer cell lines have been
reported for cucurbitacin C [154]. Cucurbitacin I has shown effective tumor growth
inhibition in breast and prostate carcinoma cell lines (MDA-MB-231, MDA-MB-468,
Panc-1), both in vitro and in vivo [145].

1.9.3 Cucurbitacin-inspired estrone analogs (CIEA)
Notwithstanding the numerous evidence showing the anticancer activities of
cucurbitacins, they are still limited as sources of pharmacological candidates due to the
following:
a) Cucurbitacins are available at only minute concentrations in their natural sources
(plants), therefore isolating them in large concentrations is tedious and usually
unsuccessful.
b) The structural complexity and diversity in functional groups or pharmacophores
of cucurbitacins makes total synthesis difficult.
c) Cucurbitacins induce toxic adverse effects in mammals even at low doses.
To overcome these challenges and also generate them as suitable drug candidates, the
Halaweish group utilized a steroidal scaffold, estrone, as starting skeleton before
installing the biologically active pharmacophores of cucurbitacins. The approach was
possible due to the similarity between cucurbitacin and estrone skeletons. The estrone
chemical structure contains a tetracyclic system that mimics the cucurbitacin skeleton
(Figure 1.8). However, the two structures differ by the presence of aliphatic ring and a
gem-dimethyl group at C-4 in the cucurbitacin structure, which is absent in the estrone
structure. Thus, utilizing estrone main skeleton, the enone or α-βunsaturated ketone side
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chain of cucurbitacins which is a significant pharmacophore for their biological activity
was assembled to create different estrone derivatives. The intent was to create new
estrone derivatives that have superior pharmacological activity but lack their estrogenic
activity. Further structural modifications such as double bond installation at C-16/C-17,
hydroxyl group substitution at C-3 with methoxy and sulfamoyl groups [155] were also
used to generate different derivatives of cucurbitacins-inspired estrone analogues (CIEA).

Figure 1.8 Design strategy for cucurbitacin-inspired estrone derivatives developed by the
Halaweish group.

1.10 Biochemical Approaches for Studying ABC Transporter Modulators
ABC transporters have the ability to recognize and transport a broad range of
molecules that include therapeutically important drugs and thus play an active role in
drug pharmacokinetics (absorption, distribution, metabolism, excretion and toxicity
(ADMET)). Compounds that interact with and influence the activity of ABC transporters
are generally referred to as modulators in some literature [91]. Modulators can behave as
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substrates (carried across the plasma membrane by the transporter), inhibitors, (impede
the transport of other compounds), inducers (amplify transporter expression) or activators
(improve transporter activity) however, one compound can have overlapping mechanisms
of action [156]. The mechanisms of action presented by different modulators are
important for therapeutic exploitation to overcome MDR in cancer. For compound
interactions with ABC transporters, a substrate drug is usually used as ‘probe’ to
investigate potential inhibitors. The mechanism of inhibitors to block transporter
mediated efflux of substrates can be one of the following ways: i) by direct inhibition of
the transporter binding sites and thus preventing the binding of the substrate, ii) inhibition
of ATP binding or hydrolysis; or iii) inhibiting the coupling of ATP hydrolysis to
substrate translocation [156]. One of the most studied substrate-inhibitor interaction with
ABC transporter systems is the drug-drug interaction involving digoxin and quinidine
with P-gp. A study reported that quinidine increased plasma digoxin levels in both P-gp
overexpressing cell lines and mouse models by inhibiting P-gp mediated transport of
digoxin into the gut and kidneys which enhanced the bioavailability of digoxin [157].
Digoxin is a cardiac glycoside and function as both a substrate and inhibitor of P-gp.
Therapeutically, digoxin is said to have a narrow effective window in which case
coadministration with P-gp inhibitors may result in toxic drug accumulations. In such
instance, inducers or activators can be useful to reduce toxicity to target tissues. Inducers
are involved in increasing transporter expression whereas activators stimulate transporter
efflux activity. Dexamethasone, doxorubicin, vinblastine and rifampicin are inducers for
both P-gp and MRP1 [91]. P-gp inducers are said to be regulated by various nuclear
factors while P-gp activators promote transporter activity by: (a) increasing the velocity
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of the transport or (b) stimulating the affinity of ATP for NBDs to increase ATP binding;
or inducing TMDs conformational changes as a result of substrate-specific binding to the
transporter [158, 159]. Inducers and activators have been used to detoxify potentially
cytotoxic compounds in many cellular models such as the blood-brain barrier, the
cardiovascular system and liver [91].
Thus, for novel drug candidates targeting multidrug resistance in cancer, it is
important to profile them with ABC transporters to elucidate their mode of action and
toxic effects, which can be used to predict their drug interaction in vivo. In view of the
important roles played by ABC transporters in the pharmacokinetics of various drugs, the
US Food and Drugs Administration (FDA), has recommended the evaluation of various
drug candidates in vitro to determine their interaction with selected ABC transporters
[160]. Some established in vitro assays for studying ABC transporter-drug interactions
applicable to this research are discussed in the sub sections.

1.10.1 High Content Fluorescence-based Screening
High throughput screening (HTS) is among one of the first techniques used in the
drug discovery process especially in the pharmaceutical industry to investigate the
interaction of new chemical entities with their biological targets. HTS performed in vitro
provides low-cost alternatives to unwarranted animal testing which might be painstaking
and time consuming. HTS assays have been employed to investigate interaction of large
compound libraries with ABC transporters. Lee et al, using a luminescence-based HTS
tested a library of 10,804 compounds on a P-gp overexpressing colchicine-selected
subline KB-8-5-11, and identified 55 novel P-gp substrates [161]. In recent years, the

38

incorporation of instruments with optical sensitivities for imaging-based screening have
more significantly improved conventional HTS techniques. Ansbro et al. reported a high
content screening (HCS) assay which was used to evaluate the activity of a kinase
inhibitor library on P-gp mediated calcein-AM efflux in MDR P-gp overexpressing KBV1 cell using a fluorescent and phase-contrast live cell imaging system [162]. The phasecontrast system allowed simultaneous identification of cell viability and density before
and after treatments, which helped to monitor cytotoxic effects in cells in situ. In
comparison, the fluorescent imaging system enabled live cell capture and quantification
of fluorescent images against a background fluorescence through segmentation masks to
obtain intracellular fluorescence intensities as a measure of the performance of the
compounds of interest. The HCS also has the advantage of not requiring multiple
washing procedures and therefore tenable for in situ cell-based systems. Recently in our
group, a high content imaging-based efflux assay was developed to investigate the
interaction of a 386 anti-cancer compound library with MRP1 using calcein-AM and
doxorubicin as fluorescent reporters in two independent studies respectively [163, 164].
The assay was effective in identifying novel inhibitors for MRP1. In this research study,
the high content imaging-based efflux assay was replicated to screen a novel compound
library of CIEA to identify inhibitors of P-gp and MRP1.

1.10.2 Flow Cytometry-based Accumulation or Efflux assays
Flow cytometry (FC) is a one of the common cell-based assays for studying the
functional characterization of ABC transporter-drug interactions. FC makes use of
fluorescent dyes that may bind to various cellular molecular targets such as DNA or
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RNA. Moreover, specific antibodies tagged with fluorescent dyes can be used to target
specific cell membrane or intracellular proteins [91]. In the FC principle, fluorescent
particles (fluorochromes) present in cells stained with the fluorescent material are able to
undergo excitation at higher energies when passed through a light source. Upon returning
to their non-excited states, the fluorochromes emit light at specific wavelengths
depending on the dye used. The fluorescence emitted is detected by specific filters and
counted by a flow cytometer. The technique allows for simultaneous measurements of
different cellular properties with several fluorochromes excited by a single laser to yield
different emission wavelengths. The activity of efflux transporters may be evaluated on
the basis of fluorescent dye accumulation/efflux or both performed on cell suspensions or
monolayers [165]. In both assays, the accumulation or efflux of the specific ABC
transporter fluorescent substrate over a time period is measured in the presence or
absence of their specific inhibitors or activators. In accumulation assays, fluorescent dye
accumulation is higher in cells with high transporter expression under conditions where
transporter is inhibited compared to the control (absence of inhibition). In contrast,
extracellular dye concentrations are measured in efflux studies as an indicator of
transporter activity. Here, the amount of dye effluxed is reduced under transporter
inhibition conditions compared to no treatment conditions. For both studies, transporter
activity can be compared with wild-type or parental cells that do not have transporter
expression [165]. Some common fluorescent substrates used in P-gp functional studies
include rhodamine 123, doxorubicin, daunorubicin, or calcein-AM [166]. Both
doxorubicin and calcein-AM or specific dyes like BCECF can be used as substrates for
MRP1 functional studies [163, 164]. It is worth noting that despite the effectiveness and
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applicability of flow cytometry, most fluorescent reporters may be limited to specific
transporter studies [166].

1.10.3 In Silico Molecular Docking Studies
In silico docking models are quick, economical and primary screening platforms
for predicting ligand-receptor interactions for novel pharmacophores in drug
development and discovery. The docking process involves generation of suitable
conformations of both ligands and receptors which are then docked using simulations to
discover lead compounds with the best binding interactions. Docking reveals both the
quantitative and qualitative characteristics of ligand binding modes to active sites of
receptor molecules using various applications [136]. Various docking models have been
used to predict binding interactions of potential modulators for P-gp, MRP1 and BCRP
which has allowed prediction of modulator binding interactions with their respective
transporters [167-169].

1.10.4 Fluorescence Spectroscopy – FRET
Fluorescence spectroscopy is an indispensable molecular probing tool used to
investigate structural-based interactions between cellular molecules. In fluorescence
resonance energy transfer (FRET), the transfer of energy between two fluorophores is
used as a measure of their interaction. One fluorophore (donor) in an excited state is able
to transfer its energy to a nearby fluorophore (acceptor) in close proximity before
returning to its ground state. The closer the distance (within10 nm) between the two
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fluorophores (the donor and acceptor), the greater the energy transfer or FRET efficiency
and greater the sensitivity to detect significant structural changes between the two
molecules. There is also a spectral overlap between donor emission and acceptor
excitation as shown in Figure 1.9.

Figure 1.9 Diagram illustrating the fundamental principle of FRET [170]

FRET-based spectroscopy has been used as a key biochemical approach to study real
time structural characteristics in ABC transporters using fluorescent proteins and
powerful imaging techniques. A study by Verhalen et al. using FRET spectroscopy was
able to elucidate the dynamics of ligand-induced structural rearrangements in the NBD
catalytic cycle of P-gp [171]. Recently, our group was able to develop genetically
engineered unique biosensors to identify novel modulators for MRP1 based on
quantitative intramolecular FRET-based interactions [172]. This FRET-based approach
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was also applied in this study to investigate CIEA compound interactions with P-gp and
MRP1.

1.11 Research Strategy and Significance
Current generation P-gp and MRP1 inhibitors are limited by toxicity, lack of
specificity and low therapeutic effect even though they have shown promising potential
in some clinical studies. The absence of no successful P-gp or MRP1 inhibitor in clinical
settings has prompted more research to focus on developing and discovering novel
compounds from natural products as desirable alternatives due to the less toxic and
structurally diverse properties of naturally-derived chemical entities. To discover novel
drug candidates with superior and safe pharmacological outcomes towards specific
cancers, the Halaweish group designed a library of estrone derivatives known as
cucurbitacin-inspired estrone analogues (CIEA). In the context that the CIEA compounds
have been developed as safe pharmacological candidates for cancer treatment and the fact
that cucurbitacins are less explored as potential ABC transporter inhibitors, our lab
collaborated with the Halaweish group with the aim to test the effect of the new CIEA
compounds on selected ABC transporters. We posed the question whether these novel
compounds will be more effective than currently known inhibitors of P-gp and MRP1.
Our primary goal was to identify novel inhibitors for P-gp and MRP1 from the large
library of CIEA. To address this goal, the following specific objectives were established:

Objective 1: Profiling a library of 81 CIEA compounds against P-gp and MRP1
overexpressing cell lines using an established high content fluorescence-based transporter
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activity assay. The inhibition of P-gp by the CIEA compounds was evaluated by using
calcein AM as fluorescent probe whereas MRP1 inhibition was detected using two
different fluorescent probes, doxorubicin and calcein red orange. The percent inhibition
by the CIEA compounds were compared with standard P-gp and MRP1 inhibitors to
identify potential hits.

Objective 2: Validation of inhibition activity of the hit compounds identified from the
HCS. In this objective, flow cytometry-based and confocal microscopy-based
accumulation assays were used to confirm the functional activity of P-gp and MRP1 in
the presence of the hit compounds.

Objective 3: Evaluation of the MDR reversing property of the hit compounds in
multidrug resistant P-gp or MRP1 overexpressing cells towards selected anticancer
agents using cell viability assays.

Objective 4: Investigating the effects of hit compounds on P-gp or MRP1 protein
expression levels using western blot technique.

Objective 5: Investigation of direct interaction of the hit compounds with P-gp or MRP1
proteins using molecular docking and fluorescence spectroscopic studies.
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Chapter 2
Characterization of cucurbitacin-inspired estrone analogues as novel inhibitors for
human permeability glycoprotein

Abstract
Multidrug resistance (MDR) remains a major challenge to cancer therapy and it is mainly
attributed to the overexpression of membrane bound ATP-binding cassette (ABC)
superfamily of transporters. Permeability glycoprotein (P-gp), a member of the ABC
transporter family contributes to multidrug resistance in various cancers by reducing the
efficacy and bioavailability of anticancer drugs. Therapeutic strategies to overcome P-gp
have failed due to lack of specificity, low potency and severe toxicity. To identify novel
inhibitors for P-gp, a high content fluorescence-based screening assay initially developed
by our group was used to screen a library of 81 novel cucurbitacin-inspired estrone
analogs (CIEAs). Defining a hit as a compound showing at least 50% percent inhibition,
the assay identified 8 compounds as inhibitors of P-gp using calcein-AM as fluorescent
reporter. The hit compounds demonstrated 50-85% range percent inhibition of P-gpmediated calcein efflux. Flow cytometry and confocal microscopy-based accumulation
assays were used to confirm inhibition of P-gp efflux activity. The ability of the
compounds to reverse resistance of P-gp overexpressing cells against vincristine,
paclitaxel and etoposide was also tested. The compounds were most effective in reversing
etoposide resistance in HEK293/P-gp cells by reducing resistance fold from 173 to
between 33-50 fold. Nonetheless, the identified compounds had no effect on P-gp
expression. Using in silico molecular docking and FRET-based spectroscopic analyses
showed that the identified inhibitor compounds directly interacted with P-gp protein. The
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results presented in this study suggest the use of cucurbitacin-inspired estrone analogues
as promising leads for future drug optimization against multidrug resistance in cancer.
Keywords: P-gp, ABC transporter, multidrug resistance, cancer therapy, anticancer
drugs bioavailability, CIEA, promising leads, drug optimization
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2.1 Introduction
A key problem leading to chemotherapeutic failure in cancer treatment is the
development of multidrug resistance (MDR). MDR is the insensitivity of tumor cells to
many anticancer agents which are different in structure, function or mechanism of action
[1]. Several mechanisms including decreased drug uptake, increased drug efflux, drug
inactivation, drug target alteration, DNA damage repair and cell death inhibition have
been reported to promote drug resistance [2, 3]. However, the best studied and major
underlying mechanism of MDR in malignant tumors is that due to overexpression of
mammalian ATP-binding cassette (ABC) transporters [4]. ABC transporters represent the
ubiquitous family of transmembrane efflux pumps that utilize energy derived from ATP
binding and hydrolysis to drive the transport of molecules against their concentration
gradient across the plasma membrane [5-7]. To date, 48 human ABC transporter genes
have been reported and they are classified into seven subfamilies, ABCA-G [8]. Amongst
the ABC transporters, P-gp (P-glycoprotein/ABCB1), MRP1 (multidrug resistance
protein 1/ABCC1) and BCRP (breast cancer resistance protein/ABCG2) are the main
drug transporters implicated in many MDR related cancers. All three transporters
facilitate active efflux of structurally and pharmacologically unrelated chemotherapeutic
agents across the plasma membrane limiting intracellular drug accumulation and drugmediated cancer cell death. [3].
P-gp, the first member of the ABC transporters discovered and the most
characterized transporter is a 170 kDa protein encoded by the human MDR1 gene. The Pgp polypeptide is made up of two homologous halves, each composed of one membrane
spanning domain (MSD) and one nucleotide binding domain (NBD) [5, 9, 10]. The
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distribution of P-gp plays a major role in protecting tissues from xenobiotics and harmful
metabolites. P-gp is typically but not exclusively, localized at the apical membranes of
epithelial cells of the colon, small intestines, liver, pancreas, kidney and uterus [11, 12].
Thus, intestinal P-gp has been suggested as the primary barrier for orally-administered
drug substrates due to limiting the bioavailability of these drugs in the body [13].
Furthermore, high expression levels of P-gp have been reported in up to 50% of gastric
cancers [14]. In humans, P-gp is biologically localized at important pharmacological
barriers such as the blood-brain and blood-nerve barriers [5, 13, 18, 22]. Expression of
P-gp at these sites is consistent with its anatomical drug-efflux role in protecting sensitive
and vital tissues from toxic exogenous compounds [10, 15-19]. More critically, P-gp
expression at the endothelial cells of the blood-brain barrier (BBB) is physically
necessary to block the net penetration of xenobiotics into the brain tissue [20]. The
absence of this can result in up to 10 to100 fold increase in drug penetration in the brain
which is clinically undesirable [5, 17, 18, 21]. However, this could be of therapeutic
relevance to clinically important drugs such as antiepileptics and antiemetics targeting the
brain or central nervous system (CNS) [22]. In the blood-testis and fetal-maternal
barriers, P-gp is expressed in stage-specific manner and plays an analogous function as in
the BBB [5]. In general, P-gp overexpression is associated with poor chemotherapy
outcome at both primary diagnosis and disease relapse stages of several cancers such as
leukemia, lymphomas, adult and childhood sarcomas and neuroblastomas [23-26]. Apart
from its drug-efflux function, P-gp also plays a significant role in other cellular processes
such as intracellular cholesterol trafficking and lipid transport, cell immunity, apoptosis
regulation and dendritic cell migration [27].
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P-gp transporter has broad substrate polyspecificity and ability to distinguish
many compounds from as tiny as 330 to 4000 Da [9, 28, 29]. Additionally, P-gp is able to
extrude many relatively hydrophobic substrates partitioned in the lipid bilayer from the
plasma membrane into the extracellular aqueous matrix [28, 30]. Two mechanistic
models accounting for these two interesting features have been hypothesized. The first
proposes a model where the transporter creates a hydrophilic pathway and drugs are
effluxed from the cytosol to the extracellular matrix through the middle of a pore
protecting the hydrophobic lipid phase [31] . The second model describes the transporter
as a ‘flippase’ that intercepts a substrate and flips it from the inner cell leaflet to the outer
and into the extracellular matrix as the substrate travels through the lipid membrane [32].
It is not surprising that P-gp transports various clinically significant drugs, including
anticancer agents such as vinca alkaloids, anthracyclines, epipodophyllotoxins, taxanes,
immunosuppressive drugs, cardiovascular agents, anthelmintics, and steroids out of the
cell [22]. Considering that P-gp recognizes and transports such broad range of
structurally unrelated compounds, finding the appropriate P-gp inhibitor to improve the
pharmacological benefit of many commonly used xenobiotics still remains a challenge.
Several attempts to circumvent P-gp mediated multidrug resistance with small
molecular entities, a process known as chemosensitization have given rise to various
pharmacological classes of P-gp inhibitors [33, 34]. The first generation P-gp inhibitors
were mostly drugs originally developed for other therapeutic applications such as
immunosuppression, antibiotic and cardiacs [35]. These P-gp inhibitors including
verapamil, cyclosporin, nifedipine, chlorpromazine, quinine and elodipine have
remarkable MDR reversal activities both in vitro and in vivo [10] [36]. However, their
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success was limited by toxicity and off-target effects [37, 38]. Verapamil, a calciumchannel blocker was reportedly associated with serious cardiotoxicity as it requires
relatively high plasma concentrations for efficacy [39]. Also, some of these inhibitors
were reported to interfere with the activity of CYP3A, an isoform of the drug
metabolizing enzyme cytochrome P450 [40, 41], suggesting that these inhibitors may
have similar substrates with CYP3A and therefore interfered with the pharmacokinetics
of chemotherapeutic drugs in combinatorial therapy. The second generation of inhibitors
such as dexverapamil, emopamil and valspodar [10, 42, 43] derived from the first
generation compounds were introduced as an improvement on dose-potency and toxicity
but still interfered with CYP3A activity [10]. The search for compounds to overcome the
second generation limitations, resulted in compounds designed using combinatorial
chemistry and structure-activity relationship approaches [10, 11, 44, 45]. These
inhibitors, the third generation compared with the first- and second generations were
more specific inhibiting P-gp function with no significant impact on CYP3A activity and
include drugs such as tariquidar, zosuquidar and laniquidar [10]. Disappointingly,
outcomes from clinical trials using these inhibitors were not clinically beneficial. A study
done by Kelly et al, revealed that co-administration of tariquidar (XR9576) with
docetaxel did not improve overall survival rate of patients with metastatic cancers even
with no toxicity [46]. Another study showed zosuquidar to be ineffective towards newly
diagnosed acute myeloid leukemia adults (older than 60 years) [47]. The reasons for the
lack of therapeutic benefits from clinical trials have been attributed to patients selection
not based solely on high P-gp expression, presence of other efflux mechanisms or lack of
accounting for other drug efflux proteins or possible occurrence of transporter
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polymorphisms that may lead to interpatient variability [48]. Thus, it appears future trials
of current generation P-gp inhibitors will be limited by their therapeutic benefit hence
alternative strategies should be sought.
Presently, the fall back to natural products as source for novel compounds has
optimistically advanced in the search for MDR modulation agents. Natural products are
important sources for new chemical entities (NCEs) in contemporary drug discovery and
design due to their diversity and amenability to semi- and total synthetic modification
[49]. Cucurbitacins (Cucs) are natural products with oxidized tetracyclic triterpenoids
derived from different species of the plant family Cucurbitaceae; with the main types
being cucurbitacins A to T [50]. Cucurbitacins are well-known to possess significant
pharmacological properties that have been explored in the treatment of various illness.
The hepatoprotective activity of cucurbitacins has been demonstrated by Bartalis and
Halaweish on HepG2 HSC-T6 cell lines [51]. Accumulated data have shown
cucurbitacins remarkable antitumor activities in various cancer profiles both in vitro and
in vivo. Particularly, cucurbitacin B has potent cytotoxic and antitumor activity in more
than 100 tumor panels e.g. breast, colon, leukemia and lung cancers [52, 53].
Cucurbitacin B has been reported to induce G2 arrest and caspase-dependent apoptosis in
human colon adenocarcinoma SW480 cells in a reactive oxidative species (ROS) –
dependent manner while activating caspases and suppressing the expression of cyclin B1
and cdc25C proteins [54]. Similarly, cucurbitacin D has reportedly shown to exert
inhibitory activities in leukemic, hepatic, colon, lung, breast and central nervous system
tumor cell lines [55]. In a recent study, cucurbitacin D suppressed metastasis in human
prostate cancer cells via a glucose regulation mechanism [56]. Cucurbitacin E, was
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reported to disrupt microtubule skeletal elements (actin and vimentin) responsible for
tumor aggression in prostrate carcinoma [57, 58]. In a combination therapy with
doxorubicin, cucurbitacin E enhanced the collective chemotherapeutic and
antitumorigenic effects in gastric cancer both in vitro and in vivo [59]. Cucurbitacins C, I
and Q are known to have antiproliferative and antitumor activities in various cancers [58,
60]. Collectively, these reports position cucurbitacins and their derivatives as prospective
drug candidates in cancer treatment. However, evaluation of cucurbitacins and its
derivatives as sources of ABC transporter (s) modulating agents is less explored. In this
work, we reckoned that exploiting the anticancer properties of cucurbitacins-derived
small compound analogues may position them as drug candidates for P-gp modulation
against multidrug resistance in cancer.
Using molecular modeling and structural activity relationships (SAR), the
Halaweish group synthesized novel compounds known as cucurbitacin-inspired estrone
analogs (CIEAs) from cucurbitacin using estrone as starting scaffold. These compounds
were designed to dual target epidermal growth factor receptor (EGFR) and mitogen
activated protein kinase (MAPK) pathways involved in cancer proliferation. In this study,
we investigated the effects of the CIEAs on P-gp activity. A library of 81 CIEA were
screened using a high content fluorescence-based transporter activity assay previously
developed in our lab [61]. From the high content fluorescence-based inhibition
experiment using calcein-AM as P-gp substrate, 8 CIEAs were identified as potential Pgp inhibitors. Using established cell-based functional assays, we validated the inhibitory
activity of the identified inhibitors and also demonstrated their ability to sensitize
multidrug resistant P-gp overexpressing cells towards different anticancer agents using
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cell viability assays. The direct interaction of the identified compounds with P-gp was
also demonstrated.

2.2 Materials and Methods
2.2.1 Chemicals
Thiazolyl blue tetrazolium bromide (MTT), doxorubicin and verapamil were
purchased from Sigma-Aldrich (St. Louis, MO). Calcein-AM was acquired from Corning
Life Sciences (Corning, NY). Vincristine and etoposide were procured from Cayman
Chemicals (Ann Arbor, MI) while paclitaxel was purchased from MedChemExpress
(Monmouth Junction, NJ). Cucurbitacin-inspired estrone analogue (CIEA) compounds
were generously provided by Dr. Fathi Halaweish (South Dakota State University,
Brookings, SD).

2.2.2 Cell lines and cell culture
HEK293/pcDNA3.1 and HEK293/P-gp, were kindly provided by Dr. Suresh V.
Ambudkar (NIH, Bethesda, MD). HEK293T cells were gifted by Dr. Adam Hoppe
(South Dakota State University, Brookings SD). HEK293 cell lines were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (GE Healthcare Life Sciences, Logan,
UT) complemented with 10% (v/v) fetal bovine serum (FBS) (Hyclone TM, GE Healthcare
Life Sciences). Cell cultures were maintained at 37 °C in a humidified incubator supplied
with 5% CO2. These conditions were utilized for succeeding cell culture techniques.
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2.2.3 High content fluorescence-based transporter activity assay for screening of
CIEA library
The assay was previously developed and optimized as reported in [61].
Fluorescence-based inhibition screening of the 81 CIEA compound library was
performed on HEK293/pcDNA3.1 and HEK293/P-gp cells using calcein-AM as
fluorescent substrate and reversan as positive inhibitor control. Cells were seeded at
density of 8 x 103 cells per well in 100 μL culture medium placed in a polymer-based 96well optical-bottom plate (Thermo Fisher Scientific, Waltham, MA) coated with poly-Dlysine (Sigma-Aldrich, St. Louis, MO) and incubated overnight. The next day, the culture
medium was removed and replaced with 80 µL serum-free medium. Drug treatment was
performed by adding DMSO (0.2% final concentration) as a negative control, reversan
(15 μM final concentration) as positive control or test compounds (10 μM final
concentration) and incubated at 37 °C for 30 min. Fluorescent substrate treatment was
performed by adding calcein-AM (0.25 μM final concentration). After 1 h, media
containing treatment were removed and cells were washed once with PBS and suspended
in 100 µL PBS containing 10 mM HEPES and 4.5% glucose prior to analysis.
An ImageXpress Micro XLS Widefield High-Content Analysis System
(Molecular Devices, Sunnyvale, CA) equipped with a 0.70 numerical aperture 60x
objective was used to acquire fluorescent images. Two independent experiments were
conducted. Images were obtained using an FITC filter for calcein-AM with excitation and
emission wavelengths of 482/35 nm and 536/40 nm respectively with exposure time set
for 100 ms. Negative and positive controls were included in every two columns to
account for post treatment drop in intracellular calcein-AM fluorescence across the plate
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over time. Fluorescent images were analyzed using the MetaXpress software (version
5.10.41, Molecular Devices) based on segmentation of fluorescent objects in the FITC
channel. A custom application component depending on the ‘Find Blobs’ module was
applied to differentiate fluorescent objects against background fluorescence by
employing segmentation masks as per parameters set for object size.

2.2.4 Calcein-AM accumulation assay
The ability of the identified CIEA compounds to inhibit P-gp-mediated calceinAM efflux was confirmed using flow cytometry. HEK293/pcDNA3.1 and HEK293/P-gp
cells were prepared in serum free DMEM culture media at 7x10 5 cell density per mL and
treated with DMSO (0.2% final concentration), negative control, verapamil (10 μM final
concentration) as positive control or test compounds (10 μM final concentration) and
incubated at 37 °C for 10 min. Cells were then treated with calcein-AM (0.25 μM final
concentration) and incubated for 30 min. Post incubation, the reaction was halted by
addition of 3 mL ice-cold PBS. Cells were pelleted, washed twice with ice-cold PBS,
resuspended in 1% paraformaldehyde (in ice cold PBS) and kept on ice for analysis.
Intracellular fluorescence was determined using BD Accuri C6 flow cytometer (BD
Biosciences, San Jose, CA) equipped with 488 nm argon laser and detected with 533/30
nm band pass filter for calcein-AM. Each experimental treatment was duplicated and
fluorescent values expressed as mean of 10,000 events. Results were collated from three
independent experiments and presented as mean ± SEM with p ≤ 0.05 compared to the
control.
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2.2.5 Doxorubicin accumulation assay
HEK293T cells were seeded in a 6-well plate, each well containing a poly-Dlysine coated (ethanol sterilized) cover glass with 2.5 x 10 5 cells in 2 mL culture medium.
After incubation overnight, cells were transiently transfected with a two-color P-gp-GFPRFP expression vector (GR 678) using jet Prime Transfection Reagent (Polyplus –
transfection SA, Illkirch, France) in accordance with manufacturer’s protocol. Following
48 h after transfection, cells were pretreated with test compounds (10 µM) for 30 min,
before incubation with doxorubicin (10 µM) for 1 h. Cells were preserved in a buffer
(4.5% glucose, 10mM HEPES and PBS containing Ca2+ and Mg2+) before analysis.
Intracellular fluorescence accumulation was viewed using an iMIC digital
microscope (TILL Photonics GmbH, Gräfelfing, Germany) equipped with a 1.35
numerical aperture 60x oil-immersion objective. GFP and doxorubicin were excited at
445 nm with emission bands at 537/26 nm and 605/64 nm respectively. RFP was viewed
in the 605/64 nm band channel after excitation at 561 nm. Images were processed with
ImageJ (NIH, Bethesda, MD).

2.2.6 Drug resistance reversal studies
The potential of the identified CIEA compounds to reverse resistance of
HEK293/P-gp cells against P-gp anticancer substrates (vincristine, paclitaxel and
etoposide) were tested using MTT colorimetric assay. HEK293/pcDNA3.1 and
HEK293/P-gp cells at a density of 5 x 104 cells/well in 100 µL culture medium were
seeded in a 96-well plate (NEST®, Rahway, NJ). After incubation overnight, cells were
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treated with 50 µL (in culture medium) test compounds (at non cytotoxic concentrations)
or 0.2% DMSO for 1 h before addition of 50 µL drug substrates (vincristine, paclitaxel
and etoposide) at varying concentrations. Following incubation for 72 h, 100 µL of
culture medium was removed and cells were treated with MTT dye (5 mg/mL in PBS) for
4 h to allow viable cells to change the yellow-colored MTT into dark-blue formazan
crystals. The MTT formazan product was dissolved with 100 µL 15% SDS containing 10
mM HCl. Cell viability was determined by measuring absorbance at 540 nm with a plate
reader, Hidex Sense Beta Plus (Turku, Finland). Three independent experiments were
performed with each done in triplicates.

2.2.7 Western blot analysis
Briefly 7 x 105 HEK293/P-gp cells were seeded in a 6-well plate at 2 mL per well
and incubated overnight before treatment with 10 µM test compounds. After 48 h, cell
lysates were prepared in radioimmunoprecipitation assay (RIPA) buffer (ThermoFisher
Scientific, Waltham, MA) containing 1x Halt Protease Inhibitor Cocktail. Lysate protein
concentrations were determined using Pierce bicinchoninic acid (BCA) Protein Assay.
Proteins (20 µg) from each treatment were subjected to electrophoresis on 10% sodium
dodecyl sulfate polyacrylamide gels before being transferred to a PVDF membrane
(EMD Millipore, Burlington, MA). The membrane was blocked and incubated overnight
at 4 °C with monoclonal P-gp antibody [C219] (GTX23364, GeneTex) and anti-α-tubulin
antibody (Sigma-Aldrich) at 1:250 and 1:5000 dilutions, respectively. Incubation with
secondary antibody (horseradish peroxidase-conjugated goat anti-mouse immunoglobulin
G (IgG; H+L, ThermoFisher Scientific) at 1:5000 dilution was performed for 1 h at room
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temperature. ABCB1 proteins were developed using western blotting luminol reagent
(Santa Cruz Biotechnology, sc-2048) and imaged with LI-COR Odyssey Fc Imaging
System. Protein band densities were analyzed with Image Studio Lite version 5.2 (LICOR Biotechnology, Lincoln, NE) software. Uneven sample loading was corrected using
the intensity of corresponding protein band relative to α -tubulin (loading control) band.
Two independent experiments were conducted and statistical testing was performed at
5% level of significance.

2.2.8 In silico molecular docking studies
The identified CIEA compounds (ligands) were prepared for docking by
generating three-dimensional conformations using Chem 3D Ultra 12.0 software
[Chemical Structure Drawing Standard; Cambridge Soft Corporation, USA (2010)],
accompanied by energy minimization using MMFF94 force field application. Human
ABCB1 homology model based on refined mouse ABCB1 was obtained from protein
data bank (PDB code: 4M1M). After bound molecules and ligands were eliminated, the
protein drug-binding pocket was prepared for docking using OpenEye software. Docking
was performed with FRED (version 2.5.1.4) and VIDA application (version 4.1.2) was
used to visualize binding poses of the ligand-receptor complex.

2.2.9 Fluorescence spectroscopic analysis
Membrane vesicles were prepared as previously described [61, 62] with slight
modifications. HEK293 cells stably transfected with 2-color P-gp (GFP and RFP)
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plasmid, GR678 were first cultured in 150 mm cell culture dishes. After 7 days or about
98% cell confluency, the cells were pelleted and stored at −80 °C till ready for use. For
membrane vesicle preparation, the frozen pelleted cells were initially thawed and
maintained in 10 mL homogenization buffer (250 mM sucrose, 50 mM Tris.HCl, 0.25
mM CaCl2, pH 7.4) supplemented with 1 tablet protease inhibitor (Santa Cruz
Biotechnology, Dallas, TX) and 10 µL benzamidine (200 mg/ml) before nitrogen bombed
at 450 psi for 5 min. Membranes from disrupted cells were obtained through
centrifugation (25,000 rpm) at 4 °C for 1 h. Membrane vesicles were formed by passing
pelleted membranes 20 times through a 27-gauge needle. Membrane vesicles protein
concentration was determined using Quick Start Bradford Protein Assay (BioRad,
Hercules, CA). For fluorescence spectroscopic analysis, two reaction mixtures were set
up: the membrane vesicle protein, 20 µg in Tris sucrose buffer (TSB) (250 mM Tris and
50 mM sucrose; pH 7.4) and the compound mixture consisting of 10 µM test compounds
in TSB. The reaction mixtures were separately pre-incubated for 5 min in a 37 °C water
bath, before they were mixed and incubated afterwards for 10 min to enable ligand
binding. To stop the reaction, samples were kept on ice prior to analysis with a
Fluorometer (model FL3-11; HORIBA Edison, New Jersey). Spectroscopic
measurements were carried out using a 50-uL quartz glass cuvette. The two-color (GFP
and RFP) P-gp protein was used as an acceptor fluorophore, therefore a previously cloned
GFP protein was used as the donor fluorophore. Excitation and emission for GFP were
attained at 465 nm and 480–650 nm respectively. Emission scans were recorded every 3 s
at 5 nm interval for 10 min. The intensities of the 2-color P-gp for compound treatments
were measured while monitoring quenching of the donor fluorophore. The FRET
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efficiency was determined by normalizing the intensity of the 2-color P-gp acceptor
ligand-free (apo) treatment with that of the donor fluorophore using the equation below:

1−(

𝐼
)𝑥 100
𝐼

where ID and IDA represent the intensities (counts per second, cps) of the donor and
acceptor fluorophores, respectively. The percent change in FRET was obtained from the
difference in FRET efficiencies of the ligand-free and the compound-induced treatments.

2.2.10 High content fluorescence inhibition screening data analysis
Analysis of fluorescence inhibition was done using MetaXpress software. The
software uses segmentation masks to determine the average fluorescent intensities from
four images captured in each well. Incorporation of segmentation mask subtracts
background fluorescence. The relative inhibition of calcein-AM efflux by test compounds
were calculated for each well using the equation below:

% 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =

𝑋 −𝑋
𝑋

𝑥 100

−𝑋

where X represents the average fluorescence intensities and T represents the test
compound. Positive and negative controls were placed in every two columns and used for
the determination of the percent inhibition for compounds within the same columns. The
assay quality and validation were assessed using Z’-factor and calculated as follows:

𝑍 − 𝑓𝑎𝑐𝑡𝑜𝑟 = 1 −

3(𝜎
|µ

+𝜎
− µ

)
|

where σ and µ represents the standard deviations and means, respectively.
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2.2.11 Statistical analysis
Statistical analyses were carried out using GraphPad Prism 8.4.3 software
(GraphPad Software, La Jolla, CA). Analysis of differences between values were
determined by application of linear mixed model. Dunnett correction was used for
multiple comparisons. Significant differences were considered at p-value less than 0.05.

2.3 Results
2.3.1 CIEA compound library screening for P-gp inhibitors
To identify novel P-gp inhibitors, a compound library of 81 CIEAs were screened
using a high content fluorescence-based transporter activity assay previously developed
by our group. Screening was performed on P-gp overexpressing cell line, HEK293/P-gp
using calcein-AM as fluorescent reporter. The positive control inhibitor (reversan 15 µM)
was considered as baseline (100% inhibition) for calculating the relative percent
inhibition for the test compounds. As shown in Figure 2.1A, the 2D scatter plot
represents the relative inhibition activity of each CIEA compound from two independent
experiments. The cut-off value defined for a positive hit was a compound with ≥50%
mean percent inhibition. With this cut-off value, 8 CIEA compounds were identified as
hits. The chemical structures of these compounds are shown in Figure 2.1B. The hit
compounds and their mean percent inhibition values are shown in Table 2.1. The
screening assay yielded a correlation value of 0.87 indicating that the two experiments
had good reproducibility. The assay also yielded an average Z’-factor value of 0.65
across all plates indicating a good assay performance.
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Table 2.1 Percentage calcein control inhibition for identified P-gp inhibitors

a

Compound

% Calcein Control Inhibition a

Reversan (Positive inhibitor)

100.00 ± 0.40

HL 4

78.29 ± 1.94

HL 15

62.27 ± 13.97

HL 16

65.35 ± 2.07

HL 20

50.41 ± 2.92

HL 21

85.32 ± 2.71

HL 22

83.27 ± 7.27

HL 77

59.73 ± 2.45

HL 80

58.68 ± 25.22

Mean ± SEM of n = 2 independent experiments
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A

B

Figure 2.1 CIEA compounds screening and selection. (A) Representation of the cellbased P-gp mediated calcein efflux inhibition screening assay. Screening of a library of
81 CIEA compounds was conducted in two independent experiments at a compound
concentration of 10 µM. The 2D plot displays the calculated relative inhibitory activity of
compounds in the two experiments with a correlation coefficient value of 0.87. Green
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dots denote compounds with mean percentage inhibition of ≥ 50%. 2D scatter plot was
generated using Sigma Plot 12.0 and correlation coefficient was calculated using MS
Excel. (B) Chemical structures of the 8 CIEA compounds identified hits.

2.3.2 Validation of identified P-gp inhibitors
Based on the results from the high content screening assay, we selected to use two
well-established cell-based functional assays to confirm the inhibition action of the hit
compounds and also eliminate false positives. To this end, we evaluated the compounds
effect on P-gp mediated calcein-AM efflux using flow cytometry. HEK293/pcDNA3.1
and HEK293/P-gp cells were treated with positive control or test compounds for 10 min
and with calcein-AM for 30 min. As shown in Figure 2.2A, verapamil at 10 µM
enhanced calcein accumulation in HEK293/P-gp cells by 10.9 fold compared to the
untreated cells (control). Moreover, all the hit compounds significantly enhanced calcein
accumulation in HEK293/P-gp cells at varying degrees (4.0 – 9.6 fold). Compounds HL
16, HL 21, HL 22 and HL 80 were very potent in inhibiting P-gp, by increasing calcein
accumulation considerably by 9.2-9.6 fold. On the other hand, no modulatory effect on
calcein accumulation was observed for the compounds in HEK293/pcDNA3.1 cells.
Our next direction was to confirm inhibition of P-gp activity by the hit
compounds on the efflux of another P-gp substrate. The effect of the compounds on P-gp
mediated doxorubicin (Dox) efflux was observed using confocal microscopy. A twocolor P-gp-GFP-RFP expression vector (GR 678) was transiently transfected into
HEK293T cells. The accessibility of mixed population of cells derived from transient
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transfection provides the means to visualize cells that pick up the vector DNA in the cell
membrane against non-transfected cells in a single image. After treatment with the
positive inhibitor or test compounds and incubation with doxorubicin, images acquired
from the GFP, RFP, and Dox channels were merged and analyzed. P-gp transport of
doxorubicin was viewed in the nucleus. As shown in Figure 2.2B, the control (DMSO)
treated cells exhibited high doxorubicin accumulation in the nuclei of non-transfected
cells, whereas doxorubicin fluorescence was undetectable in cells expressing P-gp-GFPRFP. Treatment with positive control, verapamil (10 μM), restored doxorubicin
accumulation in P-gp-GFP-RFP expressing cells. The compounds HL 15, HL 16, HL 20,
showed strong doxorubicin accumulation and hence strong inhibition similar to
verapamil. Moreover, moderate doxorubicin accumulations were observed in cells treated
with HL 4, HL 21, HL 22, HL 77 and HL 80.
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A

B

Figure 2.2 Confirmation of inhibitory effect of identified compounds on P-gp activity.
(A) HEK293/pcDNA3.1 and HEK293/P-gp cells were treated with 0.25 µM calcein-AM
at 37 °C for 30 min after pretreatment with 10 µM verapamil or test compounds for 10
min. Collated results from three independent experiments (performed in duplicates) and
presented as mean ± SEM with *p < 0.05 compared with control. (B) A two-color P-gp-
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GFP-RFP expression vector (GR 678) was transiently transfected into HEK293T cells.
After 24-48 h, cells were incubated with 10 µM test compound for 30 min, and then
treated with doxorubicin (10µM) for 1 h. Images were viewed using confocal microscope
equipped with a 1.35 numerical aperture 60x oil-immersion objective. GFP and
Doxorubicin were excited at 488 nm with emission bands at 537/26 nm and 605/64 nm
respectively. RFP was excited at 561 nm with emission band at 605/64 nm.

2.3.3 Reversal of drug resistance by identified P-gp inhibitors
The CIEA compound library under study in this work were designed to target
EGFR and MAPK pathways which play significant roles in cancer proliferation and
differentiation. Nonetheless, we decided to evaluate the capability of these compounds to
re-sensitize P-gp overexpressing cells to chemotherapeutic agents. Many reports have
established the ability of P-gp inhibitors to reverse drug resistance as crucial to the
performance of chemotherapeutic agents in cancers where P-gp is overexpressed. The
cytotoxic effect of each identified inhibitor compound on HEK293/P-gp cells was first
determined using a dose-response curve (data not shown). The non-cytotoxic
concentrations of the compounds were then selected and combined with various
concentrations of vincristine, paclitaxel or etoposide (common P-gp chemotherapeutic
substrates) and evaluated for drug resistance reversal. HEK293/pcDNA3.1 was used as
the negative control cell line. As shown in Figure 2.3A-C, The P-gp overexpressing cell
line, HEK293/P-gp, (solid red) demonstrated considerable drug resistance as anticipated
against vincristine, paclitaxel and etoposide compared with the control cell line
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HEK293/pcDNA3.1 (dotted green). Treatment with verapamil reversed resistance of
HEK293/P-gp (solid blue) towards all three chemotherapeutic drugs. Cell treatments with
vincristine, paclitaxel and etoposide with their IC 50 values and fold resistance are
represented in Table 2.2. In vincristine treatment, HEK293/P-gp cells showed 290-fold
greater resistance compared with the control, HEK293/pcDNA3.1. After treatment with
the known P-gp inhibitor, verapamil (25 µM), the fold resistance of HEK293/P-gp was
significantly reduced to 0.27-fold. Amongst the 8 hits, compound HL 77 reduced the fold
resistance of HEK293/P-gp by more than half (111-fold). Compounds HL 4, HL 15, HL
20 and HL 22 reduced resistance of HEK293/P-gp between 149 and 189-fold while
compounds HL 16, HL 21 and HL 80 showed modest reduction (between 217 – 256) in
fold resistance. The CIEA compounds at their non-cytotoxic concentrations reversed the
resistance of HEK293/P-gp cells towards paclitaxel to various extents. Compounds HL 4,
HL 16, HL 21, HL 77 and HL 80 reduced the fold resistance of HEK293/P-gp (845-fold)
to more than half (< 422.5-fold). HL 15, HL 20 and HL 22 demonstrated modest reversal
of resistance of HEK293/P-gp towards paclitaxel. Treatment of HEK293/P-gp cells with
etoposide in the absence of inhibitor, produced 173-fold more resistance than the control
HEK293/pcDNA3.1.In comparison to vincristine and paclitaxel, all the test compounds
were most effective in sensitizing HEK293/P-gp towards etoposide (reduced resistance
fold of HEK293/P-gp cells from 173 to between 33-50-fold).
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Table 2.2 Effect of the identified inhibitors on the 1C50 values of vincristine, paclitaxel and etoposide in HEK293/pcDNA3.1 and
HEK293/P-gp cells.
IC50a (µM)

Cell line/Treatment

a

Vincristine

Fold
resistanceb

Fold
resistanceb

Etoposide

Fold
resistanceb

HEK293/pcDNA3.1

0.0038 ± 0.0007

1.00

0.0016 ± 0.0002

1.00

0.0710 ± 0.0574

1.00

HEK293/P-gp

1.10 ± 0.09

290.16

1.36 ± 0.06

848.57

12.20 ± 1.96

172.68

HEK293/P-gp + Verapamil [25 µM]

0.0010 ± 0.0005

0.27

0.0031 ± 0.0024

1.92

0.6570 ± 0.0704

9.31

HEK293/P-gp + HL 4 [2 µM]

0.57 ± 0.13

148.56

0.57 ± 0.13

355.26

2.67 ± 0.57

37.58

HEK293/P-gp + HL 15 [2 µM]

0.72 ± 0.04

189.03

0.94 ± 0.06

589.89

2.50 ± 0.18

35.34

HEK293/P-gp + HL 16 [10 µM]

0.97 ± 0.05

255.70

0.39 ± 0.01

241.93

2.65 ± 0.15

37.53

HEK293/P-gp + HL 20 [2 µM]

0.63 ± 0.22

164.72

0.79 ± 0.12

496.85

2.45 ± 0.19

34.62

HEK293/P-gp + HL 21 [2 µM]

0.95 ± 0.11

250.71

0.47 ± 0.19

296.79

3.51 ± 0.31

49.64

HEK293/P-gp + HL 22 [2 µM]

0.68 ± 0.08

178.36

1.14 ± 0.12

712.35

2.38 ± 0.50

33.66

HEK293/P-gp + HL 77 [2 µM]

0.42 ± 0.09

110.57

0.40 ± 0.07

251.26

3.25 ± 0.71

46.04

HEK293/P-gp + HL 80 [10 µM]

0.83 ± 0.14

217.46

0.59 ± 0.10

370.99

2.98 ± 0.70

42.20

Paclitaxel

Mean ± SD of at least three independent experiments performed in triplicates.
Fold resistance determined by dividing the IC50 value for each treatment by the IC50 value of HEK293/pcDNA3.1 treatment with
vincristine, paclitaxel or etoposide alone.
b
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A

B

C

Figure 2.3 Reversal of drug resistance of P-gp overexpressing cells by identified
compounds towards P-gp anticancer substrates. HEK293/ P-gp cells were treated with
vincristine (A), paclitaxel (B) and etoposide (C) at increasing concentrations in the
absence or presence of verapamil (positive inhibitor) and test compounds for 72 h.
Verapamil concentration was at 25 µM; HL 4, HL 15, HL 20, HL 21, HL 22 and HL 77
were at 2 µM. HL 16 and HL 80 concentrations were at 10 µM. HEK293/pcDNA3.1
cells was used as negative control. Cell viability was evaluated with MTT colorimetric
assay. Data are representative of three independent experiments and presented as mean ±
SD (n = 3).
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2.3.4 The effect of the identified inhibitors on P-gp protein expression
Since inhibition of ABC transporter-mediated multidrug resistance mechanisms
may arise from down-regulation at the protein level, we performed western blot to
determine whether the identified P-gp inhibitors affected the expression of P-gp. As
shown in Figure 2.4, the expression levels of P-gp (170 kDa) in P-gp overexpressing
HEK293/P-gp cells were not significantly altered after treatments with 10 µM
compounds.

Figure 2.4. Expression pattern of P-gp protein in HEK293/P-gp cells treated with
identified inhibitor compounds. (A) Immunoblots of whole cell lysates prepared from
HEK293/P-gp cells treated with 10 µM test compounds for 48 h with α-tubulin used as
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loading control. Blots are representative of two independent experiments. (B) Protein
band densities were quantified using Image Studio Lite (LI-COR Biotechnology, Lincoln,
NE) software with uneven sample loading and transfer corrected per individual protein
band relative to α-tubulin. P-gp expression presented as mean ± SEM with p < 0.05
compared with control, calculated using linear mixed model and Sidak post hoc test.

2.3.5 Docking of identified P-gp inhibitors with refined mouse P-gp structure
To investigate the binding interaction of the identified inhibitors with P-gp
protein, a docking grid at the drug binding pocket of the human ABCB1 homology based
on refined mouse ABCB1 model (PDB code: 4MIM) was created and prepared for
docking using OpenEye software. The software generates consensus scoring which
signifies the virtual binding affinity of the ligands to their receptor. A lower consensus
scoring means good binding affinity of the ligand towards the receptor. From the docking
studies, all the CIEA compounds displayed better binding affinities (consensus scores: <
27) towards P-gp than the known P-gp inhibitor, verapamil (consensus score: 27) (Table
2.3). Compound HL 20 had the lowest consensus score (consensus score:1), representing
the compound with the strongest binding affinity towards the P-gp binding pocket though
with no apparent hydrogen bond interaction. Additionally, no hydrogen bond interactions
were observed for compounds HL 21 and HL 80, though both exhibited equal binding
affinities (consensus score: 19) toward P-gp. The nitrile group of verapamil hydrogen
bonded with TYR:306:A at the binding pocket (Figure 2.5A). Hydrogen bond
interactions were observed for compounds HL 4, HL 16 and HL 22 between their
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hydroxyl substituent groups and specific amino acid residues (Figures 2.5B, 2.6B, 2.8A).
Both HL 4 and HL 22 interacted with TYR:303:A. GLN:721:A residues which may be
attributed to the close similarity in their structures. HL 16 interacted with TYR:949:A
residues at the P-gp binding pocket. The amino phenyl side chain of HL 15 (Figure 2.6A)
and the hydroxyl group on C-1 of HL 77 (Figure 2.8B) were also involved with hydrogen
bond interactions with ALA:983:A and ASN:717:A respectively.

Table 2.3 Molecular docking consensus scores, and H-bonding interactions
for CIEA analogs. Verapamil used as reference drug
Compound

Mol. Wt.

Consensus score

Target H-bonding residues

Verapamil

454.602

27

TYR: 306:A

HL 4

424.572

21

TYR: 303:A; GLN 721:

HL 15

486.605

16

GLN:986:A

HL 16

538.63676

11

TYR:949:A

HL 20

562.70122

1

-

HL 21

472.57868

19

-

HL 22

424.57234

18

TYR:303:A; GLN:721:A

HL 77

502.60466

25

ASN:717:A;

HL 80

514.61536

19

-
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A

B

Figure 2.5 Visual representation for (A) Verapamil and (B) HL 4 within the binding
pocket of P-gp (PDB ID: 4MIM). Red arrows indicating location of hydrogen bonds
(green dashed lines).
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A

B

Figure 2.6 Visual representation for (A) HL 15 and (B) HL 16 within the binding pocket
of P-gp (PDB ID: 4MIM). Red arrows indicating location of hydrogen bonds (green
dashed lines).
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A

B

Figure 2.7 Visual representation for (A) HL 20 and (B) HL 21 within the binding pocket
of P-gp (PDB ID: 4MIM).
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A

B

Figure 2.8 Visual representation for (A) HL 22 and (B) HL 77 within the binding pocket
of P-gp (PDB ID: 4MIM). Red arrows indicating location of hydrogen bonds (green
dashed lines).
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A

B

Figure 2.9 Visual representation for (A) HL 80 and (B) Overlay of the binding modes of
all CIEA compounds (gray) and reference compound verapamil (green) within the
binding pocket of P-gp (PDB ID: 4MIM).
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2.3.6 Identified P-gp inhibitors induce dynamic FRET changes
FRET spectroscopy is considered an important biophysical tool for probing
interactions between cellular molecules at nanoscale distances allowing for accurate
structural information of molecules. We used the structural-based intramolecular FRET
approach to investigate our inhibitor compounds interaction with P-gp and also to
validate the results obtained from the molecular docking studies. The fluorescence
spectra representation of two-color P-gp in the presence or absence of ligands (test
compounds) and compound-induced FRET changes are shown in Figures 2.10A and B
respectively. Compounds HL 4 and HL 15 produced FRET efficiency changes (~1.5 and
1.7% respectively) which were close to that of verapamil (~1.5%). Compound HL 20
produced the highest increase in FRET efficiency (~15.3%) followed by HL 80 (~9.2%)
whiles the lowest change in FRET (~0.8%) was observed for HL 16. HL 21, 22 and 77
yielded compound-induced FRET efficiencies between ~2.7 – 5.3%.

90

Figure 2.10 Identified inhibitor (CIEA) compounds interaction with P-gp protein. (A)
Fluorescence spectra representation of two-color P-gp protein (P-gp-GFP-RFP) in the
absence or presence of ligands (identified P-gp inhibitors). GFP protein was used as
donor control. (B) Inhibitor compounds-induced FRET changes with two-color P-gp
protein. Membrane vesicles (20 µg) prepared from HEK 293T cells stably transfected
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with a two-color P-gp, GR 678 were treated with 10 µM of test compounds for 10 min
before spectroscopic analysis with the fluorometer. Verapamil and JNJ-26854165 were
included as positive and negative controls, respectively. GFP was excited at 480 nm and
RFP at 530 nm. Emission for both was achieved at 480-650 nm. Data are representative
of two independent experiments performed in triplicates. Results are presented as mean ±
SEM.

2.4 Discussion
Cancer is the second leading cause of mortality globally accounting for 1 in every
6 deaths in 2018 [63]. Multidrug resistance mediated by the overexpression of ABC
transporters is responsible for low patient survival rates in many malignancies. P-gp, the
most intensively studied MDR-transporter is recognized for its role in MDR due to its
ability to expel a broad array of drug substrates including anticancer agents out of cells.
In clinical settings, this function of P-gp serves as a first-line defense mechanism for
malignant tissues to escape the cytotoxic effects of chemotherapeutic agents. To advance
patient clinical outcomes in chemotherapy treatments, it is important to overcome P-gp
mediated MDR through inhibiting its function or down regulating its expression. To date,
no P-gp inhibitor has gone past the clinical trial stages as a result of unfavorable drug
effects [48]. Developing and discovering drugs and new compounds that target P-gp
function is therefore imperative.
The various types of cucurbitacins and their analogs have shown potential
inhibitory effects in many types of cancers [64, 65]. However, the effects of cucurbitacins
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and their derivatives on the activity of ABC drug efflux transporters in MDR is less
studied. Novel compounds known as cucurbitacin-inspired estrone analogs (CIEAs) have
currently been proven to have antiproliferative activity in hepatocellular carcinoma via
inhibiting phosphorylation pathways of EGFR and MAPK [66]. In this study, we
assessed for the first time the potential of the CIEAs to overcome P-gp-mediated MDR in
vitro. We first employed a high content fluorescence-based transport activity screening
assay to detect the inhibition of P-gp mediated efflux of calcein-AM, a known P-gp
substrate by the CIEA compounds. Calcein-AM is a cell permeable, non-fluorescent
compound that is popularly used in many modulation studies to evaluate the activity of Pgp [67, 68]. The high content fluorescence-based screening is suitable for screening large
libraries of natural and synthetic drugs. In addition to being a highly sensitive, in situ
cell-based technique, it also incorporates an imaging-based system to directly detect
cytotoxic effects. The assay identified 8 CIEA compounds as hits for P-gp inhibition with
good reproducibility (0.87 correlation value) and performance (0.65 Z-factor).
To validate the results from the high content screening assay, the inhibition
activity of the hit compounds were further evaluated on P-gp transport activity. All the
compounds displayed strong inhibition (in comparison to verapamil) of P-gp-mediated
calcein-AM efflux using flow cytometry. They also demonstrated inhibition of P-gpmediated efflux of doxorubicin, in confocal microscopy studies. Furthermore, in drug
reversal studies, the CIEA compounds demonstrated varying degrees of selectivity
towards reversal of resistance of the chemotherapeutic drugs vincristine, paclitaxel and
etoposide in P-gp overexpressing cells. For instance, all the compounds were very
effective in sensitizing HEK293/P-gp cells towards etoposide but not vincristine or
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paclitaxel. Compounds HL 16, HL 21 and HL 80 only showed modest modulatory effect
in sensitizing HEK293/P-gp cells towards vincristine while compounds HL15, HL 20
and HL 22 displayed modest reversal effect in paclitaxel resistance. Based on these
findings, we think that these CIEA compounds can specifically improve the
chemotherapeutic response of etoposide in P-gp mediated MDR cancers where P-gp is
highly expressed.
To explore the potential mechanisms of inhibition and drug resistance reversal
effect portrayed by the CIEA compounds, P-gp protein expression studies were
performed using western blot. The results indicated that the CIEA compounds have no
effect on P-gp expression at dose (10 µM) that inhibited P-gp efflux suggesting that these
compounds affect P-gp by mainly inhibiting its efflux function. It has been reported that
known P-gp inhibitors such as verapamil inhibit P-gp activity by also decreasing its
expression [69] and this might be useful in treating malignancies where P-gp is
prominently expressed. However, it is worth noting that the normal physiological defense
mechanism of P-gp in tissues such as the brain might require typical P-gp expression
levels and therefore should not be compromised. In this case it will be safe to use
compounds that only inhibit the transport function of P-gp.
The molecular basis for the polyspecificity nature of P-gp interaction with
substrates or inhibitors have been determined by Aller et al.,2009 [9]. In our quest to
investigate the CIEA compounds interaction with P-gp, molecular docking studies were
conducted. Our results revealed that all the compounds have better binding affinities
(based on consensus scoring, Table2.3) towards P-gp at the drug binding pocket than
verapamil though the overlay of the docking poses (Figure 2.9B) show the compounds

94

and verapamil all docked at similar positions in drug binding pocket. Aller et al
determined co-crystal structures of P-gp complex with the stereoisomeric cyclic
hexapeptide inhibitors (QZ59-RRR and QZ59-SSS). They reported that the ligand in
close proximity to the C-terminal half of the TMD was surrounded by three polar
residues GLN-721, GLN-986, and SER-989 [9]. Our compounds HL 4 and HL 22
interacted through hydrogen bonding with GLN-721 residue, whereas HL 15 hydrogen
bonded with GLN-986 at the drug binding pocket of P-gp. In addition, HL16 interacted
with TYR-949 which was also reported to be in close proximity to TM12. Based on our
results, we think that inhibition of P-gp transport function by the CIEA compounds may
be due to strong interaction with C-terminal transmembrane residues at the drug binding
pocket of P-gp.
From the docking studies, our attention was then directed to validate the CIEA
compounds interaction with P-gp protein. Inhibition whether competitive, noncompetitive
or uncompetitive will require direct binding of the ligand to its target. Using structuralbased fluorescent spectroscopic technique which can measure ligand-induced
intramolecular FRET changes in the P-gp protein, we showed that all CIEA compounds
directly interact with P-gp and induced varying degrees of conformational changes. This
together with our observations from the docking results reinforces our notion that the
CIEA compounds inhibitory effects on P-gp are due to direct interaction with the
transporter protein. Nevertheless, further studies are recommended to confirm and map
the precise binding site for each of the CIEA compounds on P-gp protein.
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2.5 Conclusion
Overall, we have used a high content fluorescence-based transporter activity assay
to identify cucurbitacin-inspired estrone analogues (CIEA) as potential P-gp inhibitors.
Validation of their inhibitory activity has also been demonstrated. In addition, these
compounds were able to reverse drug resistance in P-gp overexpressing cells. Finally, we
demonstrated that these compounds directly interacted with P-gp protein. This study
provides vital information on CIEA as sources of new drug discoveries for optimization
as treatment strategies to overcome MDR in cancer.
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Chapter 3
Novel compounds from cucurbitacin-inspired estrone analogues as inhibitors for
multidrug resistance protein 1.

Abstract
Multidrug resistance protein 1 (MRP1/ABCC1), a member of the ATP-binding cassette
(ABC) transporter family, actively transports diverse endogenous and xenobiotic
substrates including anticancer drugs across membrane barriers. MRP1 is widely
associated with multidrug resistance in cancer and reportedly responsible for poor patient
outcome in many hematological malignancies due to its ability to diminish the efficacy of
a broad range of anticancer agents. In this study, we identified novel inhibitors for MRP1
by utilizing a high content fluorescence-based transporter activity assay initially
developed in our lab. From screening a library of 81 novel cucurbitacin-inspired estrone
analogs (CIEAs) employing doxorubicin and calcein red orange as fluorescent reporters,
5 compounds were identified as inhibitors of MRP1-mediated doxorubicin efflux and 3
compounds were identified to inhibit calcein red orange efflux. Out of the 3 compounds
identified as inhibitors of calcein red orange efflux, 2 (HL 15 and HL 21) were also
identified as inhibitors from the doxorubicin inhibition assay. Four of the identified CIEA
compounds were selected for further validation on MRP1 inhibition using wellestablished ABC transporter cell-based functional assays. All the selected CIEA
compounds significantly increased the accumulation of MRP1 substrates, doxorubicin
and calcein red orange. Drug sensitivity studies also showed selective sensitization of
MRP1 overexpressing H69AR cells by the compounds towards the anticancer drugs,
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vincristine and SN38, however, HL 15 demonstrated good sensitization towards both
anticancer agents. Moreover, inhibition of MRP1 activity by the CIEA compounds did
not significantly alter the protein expression levels of MRP1. In silico molecular docking
and fluorescence spectroscopic studies showed inhibitor compounds directly interacted
with MRP1 protein suggesting that the CIEA compounds affect the activity of MRP1. In
summary, the findings in this work provide a novel insight in the utilization of CIEAs as
promising drug candidates against MRP1-mediated multidrug resistance in cancer.

Keywords: MRP1, ABC transporter, multidrug resistance, diminished drug efficacy,
CIEA, promising drug candidates
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3.1 Introduction
Multidrug resistance protein 1 (MRP 1) is a membrane-associated efflux pump of
the ATP-binding cassette (ABC) transporter family, an evolutionarily conserved
superfamily of ATP-dependent transporters that contribute to key cellular processes in all
organisms. In humans, there are 48 ABC transporter genes divided into seven unique
subfamilies designated ABCA through ABCG according to their domain organization
and sequence homology [1]. MRP1 (ABCC1) is the first member of the ‘C’ subfamily,
known for containing several drug transporters as well as atypical ABC transporters
including cystic fibrosis transmembrane regulator (CFTR/ABCC7) and sulfonylurea
receptor (SUR/ABCC8/9) [2-4]. Like several of the ‘C’ subfamily members, the
structural architecture of the 190 kDa MRP1 protein is characterized by a proximal NH2terminal membrane spanning domain (MSD0) in addition to the typical four core
domains: two MSD (MSD1 and MSD2) and two cytoplasmic nucleotide binding domains
(NBD1 and NBD2) observed in most ABC proteins [5-8]. The MSD1 and MSD2 contain
six transmembrane (TM) helices each and form the substrate translocation ‘pore’ through
which substrates are transported [9]. The transport process is powered by ATP binding
and hydrolysis at the catalytic core of the 2 NBDs, which is defined by a distinct
functional asymmetry [10, 11]. The function of the MSD0 although proposed to play a
role in dimerization still remains poorly understood [12].
MRP1 is the primary transporter of endogenous anionic substrates such as
glutathione (GSH), cobalamin, bilirubin, estradiol glucuronide (E217βG) and cysteinyl
leukotriene (LTC4 [13-15]. The ATP-dependent transport of the antioxidant GSH and the
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pro-inflammatory molecule, LTC4, makes MRP1 an essential mediator in cellular redox
homeostasis, cell differentiation, proliferation and immunological reactions. Owing to
these essential cellular functions, it is not surprising that MRP1is associated with the
pathophysiology of many metabolic, cardiovascular, neurological, immunological and
tumor related diseases in humans [16-19]. MRP1 also mediates the efflux of sulfateconjugated drugs, or unconjugated drugs concertedly with free glutathione many of
which include antineoplastic agents like vinca alkaloids, epipodophyllotoxins,
methotrexate, camptothecins and many clinically important therapeutics e.g. antibiotics,
antivirals, antidepressants, statins and metal oxyanions [20, 21].
In normal tissues, MRP1 is distributed in the lung, gastrointestinal tract, cardiac,
liver, pancreas, adrenal cortex, skin and skeletal muscle but mainly localized to
basolateral membranes of polarized epithelia [22]. Importantly, MRP1 is expressed in
pharmacological sensitive barriers and therefore exerts chemoprotective functions in
tissues of the brain, testes and placenta [23]. Notwithstanding, MRP1 is the most
prevalent drug efflux transporter implicated in multidrug resistance (MDR) in cancer
besides P-gp. Since its discovery in a doxorubicin-selected lung cancer cell line, MRP1
overexpression in malignant diseases especially hematologic and solid tumors have also
been confirmed [24-27]. MRP1 confers resistance to tumor cells by actively extruding a
large number of structurally unrelated chemotherapeutics out of the cells thereby
affecting the overall drug absorption, disposition and efficacy. The consequence is poor
clinical outcome in many patients particularly with non-small lung cancer, acute myeloid
leukemia, (AML), and breast cancer [26, 28, 29]. Clinical investigations have also shown
a high correlation between overexpression of MRP1 and aggressive or multidrug
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resistance traits in tumors [28]. Particularly, various studies on childhood neuroblastoma
have shown evidence of high MRP1 expression levels as the key individual prognostic
biomarker of poor patient outcome [30, 31]. Furthermore MRP1, is reported as the target
of MYCN, the main oncogene frequently amplified in human neuroblastoma [32].
Generally, the strategy to overcome ABC transporter-mediated MDR in cancer is
the pharmacological suppression of drug transporters to restore sensitivity of cancer cells
to anticancer drugs. A number of inhibitors have been developed and progressed to the
clinical trial stages for the first drug efflux transporter, P-gp since its discovery over 4
decades ago [33, 34]. In contrast, the search for MRP1 inhibitors is still at the infancy
stage and prominent MRP1 inhibitors such as leukotriene D4 (LTD4) receptor antagonist,
MK571 and ONO-1078 [35, 36]; the anion transport inhibitor, probenecid [37] and the
nonsteroidal anti-inflammatory drug indomethacin [38, 39] are still currently being
studied for their activity on MRP1 function. In addition, known P-gp inhibitors such as
cyclosporine A, PC-883 (valspodor), and verapamil [40] and natural products e.g.
agosterol and flavonoids [41-44] have all been reported to have inhibitory action on
MRP1. Most recently, tyrosine kinase inhibitors (TKIs) such as ibrutinib and lapatinib
have also demonstrated potent MRP1 inhibition [45, 46]. Unfortunately, the action of
some of these MRP1 inhibitors have been far from satisfactory due to toxicity and severe
side effects among other reasons [47-49]. The development of more structurally diverse,
highly potent, less toxic and selective MRP1 inhibitors is thus desirable.
In our continuous effort to search for novel MRP1 inhibitors, we explored novel
compound library known as cucurbitacin-inspired estrone analogs (CIEAs) as potential
MRP1 inhibitors. CIEAs are natural products derived from cucurbitacins D, a class of
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oxidized tetracyclic triterpenoids isolated from the plant family Cucurbitaceae.
Cucurbitacins are well-known for their anticancer, antiproliferative and antiinflammatory properties in many types of cancers [50-52]. The CIEAs were designed
using estrone as starting steroidal scaffold targeting the EGFR and MAPK pathways
involved in the proliferation activity of hepatocellular cancer [53]. In the present study,
we focused on using various in vitro ABC transporter functional evaluation assays and in
silico molecular docking studies to assess the effects of the CIEA compounds on MRP1
activity.

3.2 Materials and Methods
3.2.1 Chemicals
Doxorubicin, calcein red orange, poly-D-lysine and thiazolyl blue tetrazolium
bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, MO). Vincristine and
MK571 were procured from Cayman Chemicals (Ann Arbor, MI). SN38 was purchased
from MedChem Express (Monmouth Junction, NJ). Novel compound library consisting
of 81 CIEAs were generously provided by Dr. Fathi Halaweish (South Dakota State
University, Brookings, SD).

3.2.2 Cell lines and cell culture
MRP1 overexpressing cells, H69AR and its parental H69 were purchased from
American Type Culture Collection (ATCC) (Manassas, VA) and were cultured in RPMI
1640 (ATCC) medium. HEK293T cells were a kind gift from Dr. Adam Hoppe (South
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Dakota State University, Brookings, SD) and were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) (GE Healthcare, Marlborough, MA). Both media were
supplemented with 10% (v/v) fetal bovine serum (FBS) (Hyclone TM, GE Healthcare Life
Sciences). All cell lines were maintained at 37 °C in a humidified incubator supplied with
5% CO2. H69AR cells were challenged with doxorubicin (0.8 μM) once monthly and
cultured for 7 days drug-free before use.
3.2.3 Fluorescence-based transporter activity assay via high content screening
Assay development and optimization were conducted as previously reported [54].
The assay was performed on H69AR cells using doxorubicin and calcein red orange as
fluorescent substrates. Briefly, cells were seeded onto a 96-well optical-bottom plate with
polymer base (Thermo Fisher Scientific, Waltham, MA) coated with poly-D-lysine
(Sigma-Aldrich, St. Louis, MO) at a final concentration of 6 x10 4 per well in 100 μL
culture medium. After incubation overnight, media was replaced with 80 μL serum free
media prior to treatment with test compounds and fluorescent substrates. Treatments were
done using DMSO as negative control at 0.2% final concentration, MK571 as positive
control at 50 μM final concentration and 10 μM final concentration for test compounds.
For doxorubicin inhibition screening, cells were initially treated with test compounds or
positive control for 30 min before incubation with doxorubicin (10 μM final
concentration) for 2 h. For calcein red orange screening, cells were similarly treated with
test compound or positive control for 30 min, calcein red orange (0.25 µM final
concentration) was added and incubated for additional 30 min. Post incubation with
fluorescent substrates, cells were rinsed once with PBS and loaded with 100 µL of PBS
containing 10 mM HEPES and 4.5% glucose for analysis.
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Fluorescent images were acquired using ImageXpress Micro XLS Widefield HighContent Analysis System (Molecular Devices, Sunnyvale, CA) equipped with a 0.70
numerical aperture 60x objective. Four images were acquired from each well in the Texas
red channel for both fluorescent reporters with excitation and emission at 562/40 nm and
624/40 nm respectively, and exposure time set for 100 ms. A possible limitation of
fluorescence experiments in 96-well plates is the gradual decrease in fluorescence across
the plate due to drop in intracellular fluorescence over time. To account for this, negative
and positive controls were included in every two columns across the plate. The screening
assay was conducted in two independent experiments. Fluorescent intensity values from
images were analyzed using MetaXpress software (version 5.10.41, Molecular Devices).
The analysis involved segmentation of fluorescent objects in the Texas red channel by a
custom application model built from the ‘Find Blobs’ module. The model distinguishes
fluorescent accumulation against a background by applying segmentation masks
depending on specifications set for object size.

3.2.4 Fluorescence accumulation assay by flow cytometry
Using the same fluorescent substrates (doxorubicin and calcein red orange)
employed in the high content screening assay, we validated the inhibition activity of the
identified hit compounds employing flow cytometry. H69 and H69AR cells at a density
of 7 x105 were suspended in 1 mL serum free media and treated with negative control
(DMSO at 0.2% v/v) or positive control (MK571 at 50 μM final concentration) or test
compound (10 μM final concentration). For MRP1-mediated doxorubicin efflux,
treatments were incubated for 1 h at 37 °C after which doxorubicin (10 μM final
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concentration) was added and further incubated for 2 h. MRP1-mediated calcein red
orange efflux assay involved pretreatment with negative, positive controls and test
compounds for 10 min at 37 °C before addition of calcein red orange dye (0.25 μM final
concentration) and further incubation for 30 min. After incubation, the reaction was
ceased by addition of 3mL ice-cold PBS to each treatment. Cells were pelleted, washed
twice with ice-cold PBS and then suspended in 1% paraformaldehyde (in ice cold PBS)
for analysis. Accumulated intracellular fluorescence was determined using BD Accuri C6
flow cytometer (BD Biosciences, San Jose, CA) equipped with 488 nm argon excitation
laser. Doxorubicin and calcein red orange were both detected with > 670 nm band pass
filter. Two independent experiments were conducted with each sample duplicated. For all
samples, 10,000 events were collected and mean fluorescent intensities expressed as
percentage of the control.

3.2.5 Doxorubicin localization assay using confocal microscopy
To further validate the inhibition activity of the identified compounds, we used
confocal microscopy to qualitatively demonstrate the effect of the compounds on MRP1mediated efflux of an anticancer drug. We elected to use doxorubicin as the common
anticancer and fluorescent substrate of choice since the compounds identified as
inhibitors using calcein red orange were also detected with doxorubicin in the high
content screening. HEK293T cells at a density of 2.5 x 10 5 cells/well in 2 mL complete
media were plated into a 6-well plate containing a poly-D-lysine coated (ethanol
sterilized) cover glass and incubated at 37 °C. At 90 % confluency, cells were transiently
transfected with an MRP1-GFP expression vector using jetPrime Transfection Reagent
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(Polyplus – transfection SA, Illkirch, France) according to manufacturer’s protocol. After
48 h, cells were treated with negative control (DMSO at 0.2% v/v) or positive control
(MK571 50 μM final concentration) or test compound (10 μM final concentration) for 30
min, and then with doxorubicin (10 µM) for 1 h. Prior to microscopic analysis, cells were
maintained in a buffer (4.5% glucose, 10mM HEPES and PBS) containing Ca 2+ and
Mg2+. MRP1 and doxorubicin localization were imaged using an iMIC digital
microscope (TILL Photonics GmbH, Gräfelfing, Germany) equipped with a 1.35
numerical aperture 60x oil-immersion objective. Both GFP and doxorubicin were excited
at 445 nm with emission attained at 537/26 nm and 605/64 nm respectively. Images were
processed using ImageJ (NIH, Bethesda, MD).

3.2.6 Drug sensitivity studies
The identified MRP1 inhibitors were investigated for their ability to re-sensitize
multidrug resistant cells to chemotherapeutic drugs using MTT colorimetric assay. H69
and H69AR cells were plated in a 96-well plate (NEST®, Rahway, NJ) at a concentration
of 2.5 x 104 cells/well in 100 µL culture medium. The next day, 50 µL of medium
containing test compounds at non- cytotoxic concentrations were added to cells 1 h prior
to treatment with 50 µL of the chemotherapeutic drugs (vincristine and SN38) at varying
concentrations. After incubation for 96 h, 100 µL of culture medium was removed and
cells were treated with MTT dye (5 mg/ml in PBS) for 4 h. The MTT formazan product
was dissolved in 100 µL 15% SDS containing 10 mM HCl. Cell viability was determined
by measuring absorbance at 570 nm with a plate reader, Hidex Sense Beta Plus (Turku,
Finland).
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3.2.7 Immunoblot analysis
H69 and H69AR cells were seeded in a 6-well plate at 1 x 10 6 cell density in 2
mL culture medium per well. After 24 h, cells were treated with or without 10 µM test
compounds. H69 was used as negative control cell line. Cell lysis was performed in
radioimmunoprecipitation assay (RIPA) buffer (ThermoFisher Scientific, Waltham, MA)
containing 1x Halt Protease Inhibitor Cocktail after 48 h. Lysate protein concentrations
were determined using Pierce bicinchoninic acid (BCA) Protein Assay. Proteins at 20 µg
were subjected to electrophoresis on 8.0 % sodium dodecyl sulfate polyacrylamide gels
before being transferred to PVDF membranes (Immobilon® Millipore, Burlington, MA).
Membranes were blocked prior to antibody treatments with rabbit monoclonal anti MRP1
antibody [EPR21062] (1:250; Abcam, ab233383) and anti α-tubulin antibody (1:5000;
Sigma-Aldrich) and incubated overnight at 4 °C. This was followed by treatment with
horseradish peroxidase-conjugated goat anti-mouse IgG(H+L) (1:1000; ThermoFisher
Scientific) secondary antibody for 1 h at room temperature for both MRP1 and α-tubulin.
MRP1 proteins were developed using Western Blotting Luminol reagent (Santa Cruz
Biotechnology, sc-2048) and immunoblots visualized with an LI-COR Odyssey Fc
Imaging System. Resulting protein bands were analyzed with Image Studio Lite version
5.2 (LI-COR Biotechnology, Lincoln, NE), and the correction for uneven sample loading
and transfer achieved by applying the relative bands for the loading control (α-tubulin).
Three independent experiments were conducted.
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3.2.8 Molecular docking studies
The identified inhibitors were subjected to in silico molecular docking with
MRP1 protein structure. The structures of the inhibitors (ligands) were prepared for
docking through energy minimizations using MMFF94 force field application followed
by ligand conformations utilizing OMEGA application. The binding pocket of the
receptor, bovine MRP1 (PDB code: 5UJ9) was generated via OpenEye software and
docking was conducted using FRED (version 2.5.1.4). Docked poses were visualized
using Vida application (version 4.1.2).

3.2.9 Fluorescence spectroscopic analysis
Membrane vesicles were prepared from HEK293 cells stably transfected with
GFP- MRP1 (donor control containing only GFP) or a two-color (GFP and RFP) MRP1
plasmids. Steady-state fluorometry using experimental conditions as previously described
[55] with slight modifications was performed to determine the intramolecular
fluorescence resonance energy transfer (FRET) changes of apo (ligand-free) and ligandbound MRP1. Briefly, 10 µg MRP1- enriched membrane vesicles in Tris sucrose buffer
(250 mM Tris and 50 mM sucrose; pH 7.4) initially incubated for 2 min in a 37 °C water
bath were treated with 10 µM of test compounds and re- incubated for 10 min.
Fluorescent spectroscopic measurements were carried out using a 50-uL quartz glass
cuvette with the Fluorometer model FL3-11 (HORIBA Edison, New Jersey). GFP
excitation and emission was achieved at 465 nm and 480–650 nm respectively, with
excitation and emission slit widths of 5 nm. The GFP-MRP1 (donor) emission scan was
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collected whiles monitoring quenching of the emission peaks from the two-color MRP1
(acceptor) in the absence or presence of a ligand. Emission scans were collected every 3 s
at 5 nm interval over a period of 10 min. FRET efficiency was calculated using the
following equation:

1−(

𝐼
)𝑥 100
𝐼

where ID and IDA represent the intensities (counts per second, cps) of the donor and
acceptor fluorophores, respectively. The transfer efficiencies of compound-induced
samples were normalized with that of the apo condition to obtain the percent change in
FRET.

3.2.10 High content fluorescence inhibition screening data analysis
Analysis of fluorescence inhibition was performed with MetaXpress software. For
each well, four images were captured. Using segmentation masks to subtract background
fluorescence, the mean fluorescent intensity of each well was determined from the
average fluorescent values of the four images. The relative efflux inhibition of the
fluorescent substrates (doxorubicin or calcein red orange) by each test compound was
determined for each well using the following equation:

% 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =

𝑋 −𝑋
𝑋
−𝑋

𝑥 100

with X representing the average fluorescence intensities of the test compound (T).
Positive and negative controls were placed in every two columns and used for the
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determination of the percent inhibition for compounds within the same column. The
assay quality and validation were assessed using Z’-factor and calculated as follows:

𝑍 − 𝑓𝑎𝑐𝑡𝑜𝑟 = 1 −

3(𝜎
|µ

+𝜎
− µ

)
|

where σ and µ represents standard deviations and means, respectively.

3.2.11 Statistical analysis
Statistical analyses were carried out using GraphPad Prism 8.4.3 software
(GraphPad Software, La Jolla, CA). Differences between values were analyzed by
applying linear mixed model and Dunnett correction used for multiple comparisons.
Significant differences were considered at p-value less than 0.05.

3.3 Results
3.3.1 Fluorescence imaging-based high-content screening of CIEA library for
MRP1 inhibitors
A high content fluorescence inhibition screening assay originally developed in our
lab was used to screen a library of 81 novel CIEA compounds to identify inhibitors for
MRP1 using doxorubicin and calcein red orange fluorescent substrates which our lab
have also established as suitable for identifying inhibitors for MRP1. The 2D scatter plots
represent the relative percent inhibition by the test compounds on MRP1-mediated efflux
of doxorubicin and calcein red orange respectively (Figures 3.1A and 3.1B) determined
from two independent experiments. The Z’-factor which demonstrates the assay
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performance and reproducibility obtained for doxorubicin and calcein red orange
inhibition assays were 0.50 and 0.59 respectively. The screening was conducted on
doxorubicin resistant lung cancer cell line, H69AR. A positive hit was defined as a
compound with mean percent inhibition of at least 45 % from the two experiments.
MK571 (50 μM) was used as positive control baseline (100 % inhibition) for determining
the relative percent inhibition for the test compounds (10 μM). Five compounds were
identified as inhibitors of MRP1-mediated doxorubicin efflux and three compounds
identified as calcein red orange efflux inhibitors, including 2 compounds (HL 15 and HL
21), which were also identified from the doxorubicin inhibition assay (Table 3.1). From
the hit compounds obtained from both screening assays, four compounds (HL 15, HL 21,
HL 38 and HL 53) with chemical structures shown in Figure 3.2) were selected for
further characterization.
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Doxorubicin

A

B

Calcein red orange

Figure 3.1. Performance of the high content fluorescence-based MRP1-mediated
doxorubicin and calcein red orange inhibition screening assay. Screening of a library of
81 CIEA compounds was conducted in two independent experiments at a compound
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concentration of 10 µM using doxorubicin (A) and calcein red orange (B) as fluorescent
substrates. The 2D plot displays the calculated percentage inhibition of compounds in the
two experiments. Red and Orange dots denote compounds with mean percentage
inhibition of ≥ 45% for doxorubicin and calcein red orange, respectively. 2D scatter plots
were generated using Sigma Plot 12.0.

Figure 3.2 Chemical structures of 4 selected CIEA compounds identified as hits from
both doxorubicin and calcein red orange screening assays.
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Table 3.1 Percentage doxorubicin and calcein red orange control inhibition for identified
MRP1 inhibitors
Compound

% Doxorubicin

% Calcein Red Orange

control inhibition a

control inhibition a

MK571

100.0 ± 0.0

100.0 ± 0.0

HL 10

78.3 ± 61.5

HL 15

55.4 ± 14.1

58.0 ± 8.6

HL 21

45.2 ± 8.9

81.4 ± 16.4

HL 27

51.2 ± 3.7

HL 38

81.5 ± 4.7

HL 53

76.8 ± 12.7

a

Mean ± SEM of n = 2 independent experiments

3.3.2 Validation of identified CIEA hit compounds
The selected compounds were validated for their inhibition activity on MRP1
function by employing two well-established ABC transporter functional assays. First, the
compounds effect on MRP1 efflux of doxorubicin and calcein red orange were
determined using flow cytometry. H69 and H69AR cells were incubated with the test
compounds and the fluorescent substrates at specific time points (as indicated in the
Materials and Methods section). As shown in Figure 3.3A, all the identified compounds
(10 μM) significantly inhibited MRP1-mediated efflux of doxorubicin and thus enhanced
doxorubicin accumulation in drug resistant H69AR cells but had no significant effect on
H69, the drug sensitive cell line. The positive control MRP1 inhibitor, MK571 (50 μM)
increased intracellular levels of doxorubicin by 2.2 fold. Amongst the compounds, HL 15
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was the most effective doxorubicin efflux inhibitor, increasing doxorubicin accumulation
by ~ 2.0 fold. Modest doxorubicin accumulations (1.3-1.5 fold enhancement) were
observed for compounds HL 21, HL 38 and HL 53. From the results of the calcein red
orange accumulation assay (Figure 3.3B), treatment of H69AR cells with HL 15 and HL
21 also enhanced intracellular calcein red orange levels by ~2.7 fold although MK571 (50
μM) was seen to increase calcein accumulation significantly by 4.5 fold. The test
compounds on the other hand, showed only weak modulatory effect in H69 cells.
In the next validation assay, the effects of the compounds on MRP1-mediated
efflux of doxorubicin in live cells were qualitatively assessed using confocal microscopy.
This is because doxorubicin identified more hit compounds amongst which 2 compounds
were also identified with calcein red orange in the high content screening assay. An
MRP1-GFP encoding vector was transiently transfected into HEK293T cells. After cells
were treated with controls or test compounds, localization of doxorubicin in the nucleus
was visualized. As shown in Figure 3.3C, the nuclei of non-transfected cells in the
control showed high accumulation of doxorubicin whiles doxorubicin was not detectable
in MRP1-GFP transfected cells. Treatment with MK571 (50 μM) restored doxorubicin
localization in MRP1-GFP expressing cells. Compounds HL 15, HL 21, HL 38 and HL
53 all enhanced doxorubicin accumulation in cells expressing MRP1 similar to MK571.
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C

Control

MK571

HL 15

HL 21

HL 38

HL 53

Figure 3.3 Validation of identified compounds inhibitory action on MRP1 efflux
activity. (A) Doxorubicin accumulation assay. H69 and H69AR cells were pre-treated
with 50 µM MK571 or test compounds for 2 h before incubation with 10 µM doxorubicin
at 37 °C for 2 h. Fluorescence intracellular doxorubicin accumulation was measured
using flow cytometry, with excitation and emission wavelengths of 480 and 670 (LP) nm,
respectively. (B) Calcein red orange accumulation assay. H69 and H69AR cells were pretreated with 50 µM MK571 or test compounds for 10 min before incubation with 25 nM
calcein red orange at 37 °C for 30 min. Intracellular calcein red orange accumulation was
quantified using flow cytometry, with excitation and emission wavelengths of 480 and
585/40 nm, respectively. (C) Doxorubicin localization assay. An MRP1-GFP expression
vector (green) was transiently transfected into HEK293T cells. After 48 h, cells were
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incubated with 10 µM test compound for 30 min and then with 10µM doxorubicin (red)
for 1 h. Images were obtained using confocal microscope. GFP and Doxorubicin were
excited at 488 nm with emission bands of 537/26 nm and 605/64 nm, respectively.

3.3.3 Effects of the identified MRP1 inhibitors (CIEAs) on the efficacy of anticancer
drugs
MTT colorimetric assay was used to evaluate the ability of the identified MRP1
inhibitors (CIEA compounds) to reverse resistance of MRP1 overexpressing cancer cells
(H69AR) to selected anticancer agents. The cytotoxic effect of the test compounds on
H69AR cells were first analyzed to select compound concentrations that did not
significantly affect cell viability (data not shown). The non-cytotoxic compound
concentrations were used in combination with various concentrations of vincristine and
SN38, prominent MRP1 substrates. Presented in Table 3.2 are the IC 50 and fold resistance
values of the drug resistant cell line, H69AR and its control parental cell line, H69 treated
with vincristine and SN38 in the presence or absence of test compounds. As expected,
MRP1 overexpressing H69AR cells showed higher resistance to vincristine (Figure 3.4A,
red solid line) and SN38 (Figure 3.4B, red solid line) alone compared to H69 (green dash
line) and produced resistance folds of 12.3 and 206.4 respectively. Addition of positive
inhibitor, MK571 (10 μM) lowered the resistance folds of H69AR cells to vincristine and
SN38 from 12.3 to 5.2 fold and 206.4 to 69.5 fold respectively. Compounds HL 15, HL
21 and HL 38 re-sensitized H69AR cells to vincristine by reducing resistance from 12.3
fold to the range of 8.2 to 9.6 fold. In contrast, HL 53 did not affect the sensitivity of
H6AR to vincristine. All of the test compounds significantly reversed resistance of
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H69AR to SN38 by reducing resistance fold from 206 to 60 -100 fold range. However,
HL 15 and HL 38 were the most potent sensitizing H69AR to SN38, reducing resistance
fold from 206.4 to 60.6 and 78 fold respectively.

A

B

Figure 3.4 Reversal of drug resistance in H69AR cells by the identified MRP1 inhibitors
towards anticancer substrates. H69 and H69AR cells were treated with vincristine (A)
and SN38 (B) at increasing drug concentrations in the absence or presence of MK571 and
test compounds for 72 h . MK571 concentration was at 10 µM; HL 15, HL 38 and HL 53
were at 2 µM while HL 21 concentration was at 0.4 µM. Cell viability was evaluated
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using MTT colorimetric assay. Data are representative of at least three independent
experiments and presented as mean ± SD.

Table 3.2 The effects of identified MRP1 inhibitors on the 1C 50 values of vincristine and
SN38 in H69 and H69AR cells
IC50a (nM)

Cell line/Treatment

H69
H69AR
H69AR + MK571 [10
H69AR + HL 15 [2 µM]
H69AR + HL 21 [0.4 µM]
H69AR + HL 38 [2 µM]
H69AR + HL 53 [2 µM]

Vincristine

Fold
resistanceb

1.90 ± 0.16
23.35 ± 5.92
9.91 ± 3.11
16.69 ± 1.99
15.56 ± 3.05
18.12 ± 1.11
24.92 ± 4.95

1.00
12.30
5.22
8.74
8.20
9.55
13.13

SN38

3.57 ± 1.28
736.40 ± 61.62
247.80 ± 19.85
216.27 ± 58.12
631.67 ± 139.21
278.30 ± 78.24
357.03 ± 25.54

Fold
resistanceb
1.00
206.41
69.46
60.62
101.37
78.01
100.07

a

Mean ± SD of at least three independent experiments performed in triplicates.
Fold resistance determined by dividing the IC 50 value for each treatment by the IC50
value of H69 cells treated with vincristine or SN38 alone.
b

3.3.4 The effects of identified CIEA hits on MRP1 protein expression
We assessed whether the inhibitory action demonstrated by the identified
compounds had any effect on MRP1 expression at the protein level. Immunoblot analysis
(Figure 3.5A- B) conducted on MRP1 overexpressing H69AR cells showed that the
identified CIEA compounds (10 µM) have no significant effect on MRP1 protein
expression.
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Figure 3.5 The effect of CIEA compound inhibitors on MRP1 protein expression. (A)
Representative immunoblot of whole cell lysates prepared from H69AR cells treated with
or without 10 µM test compounds for 48 h. (H69 cells were used as negative control).
MRP1 proteins were detected using goat-anti-rabbit IgG (H+L) (1:1000) and
confirmation of equal protein loading detected with anti α-tubulin antibody (1:5000). (B)
Protein band densities were quantified using Image Studio Lite (LI-COR Biotechnology,
Lincoln, NE) software with uneven sample loading and transfer corrected per individual
protein band relative to α-tubulin. Results are representative of at least 2 independent
experiments.
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3.3.5 Molecular docking analysis of the identified inhibitors with bovine MRP1
The identified MRP1 inhibitors were docked with bovine MRP1 (91% sequence
identity with human MRP1 protein) Cryo-EM structure using MK571 as reference
inhibitor. The best-scored poses of the compounds are represented in Figures 3.6-3.8. The
hydroxyl group at carbon 17 and the triazole moiety in HL 15 formed hydrogen bond
interactions with ARG:593:A residues of bovine MRP1 (Figure 3.6B). In addition, HL
15 showed equal consensus score (Table 3.3) with MK571 suggesting that both
compounds may have similar binding affinities towards MRP1. Compound HL 21
hydrogen bonded with ASN:1244:A residues in MRP1 however with a higher binding
affinity (consensus score: 8) than MK571. Compounds HL 38 and HL 53, all showed
lower consensus scores (6) than the reference compound though with no observable
hydrogen bond interactions.
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Table 3.3 Molecular docking consensus scores, molecular weights and H-bonding
interactions for identified MRP1 inhibitors (CIEA analogs). MK571 used as reference
drug.
Compound

Mol. Wt.

Consensus score

Target H-bonding
residues

MK571

454.602

10

-

HL 15

424.572

10

ARG: 593:A

HL 21

486.605

8

ASN:1244:A

HL 38

538.637

6

-

HL 53

562.701

6

-
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B

Figure 3.6 Dock poses for (A) MK571 and (B) HL 15 within the binding pocket of
bovine MRP1 (PDB ID: 5UJ9). Red arrows indicate location of hydrogen bonds (green
dashed lines).
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A

B

Figure 3.7 Dock poses for (A) HL 21 and (B) HL 38 within the binding pocket of bovine
MRP1 (PDB ID: 5UJ9). Red arrows indicate location of hydrogen bonds (green dashed
lines).
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A

B

Figure 3.8 Dock poses for (A) HL 53 and (B) Overlay of all compounds along with
MK571 (green) within the binding pocket of bovine MRP1 (PDB ID: 5UJ9).
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3.3.6 Identified CIEA hits interaction with MRP1
To determine if the identified MRP1 inhibitors directly interact with MRP1
protein, we employed a novel structural-based approach [56]. This approach makes use of
two-color recombinant protein engineered from fusing a GFP and RFP with MRP1
protein structure. The two-color MRP1 protein can potentially detect the direct
interaction of ligands with MRP1 and determine the intramolecular FRET changes as an
indicator of conformational changes as a result of ligand binding to MRP1 [57]. Here,
fluorescence spectroscopic analysis was used to measure the changes in FRET efficiency
that results upon interaction of the CIEA compounds with the two-color MRP1 protein.
MK571 was used as positive control and JNJ-26854165, which our group has previously
reported as showing no interaction with MRP1 [58] was used as the negative control. The
representative fluorescence spectra of the donor control (containing only GFP) and the
apo (ligand-free) and ligand-bound (test compound) with two-color MRP1 is shown in
Figure 3.9A. From the FRET results, (Figure 3.9B), all the identified CIEA compounds
showed an increase in FRET efficiency relative to the apo condition indicating that they
directly interact with MRP1. Among the compounds, HL 15 showed the highest FRET
change (∼7%) while HL 21 induced the smallest change (∼3%). As expected, MK571
interacted with MRP1, while JNJ-26854165 yielded no significant FRET change relative
to the apo FRET condition.
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A

B

Figure 3.9 Compound induced intramolecular FRET measurements. (A) Representative
fluorescence spectra of apo (ligand -free) and ligand –bound (test compounds) of two-
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color MRP1 protein (MRP1-GFP was used as donor control). (B) Compound-dependent
FRET changes with two-color MRP1 protein. MRP1 membrane vesicles (10 µg) in Tris–
sucrose buffer was prepared and incubated with 10 µM of test compounds for 10 min
prior to FRET measurements using the fluorometer. GFP and RFP excitations were
achieved at 465 nm and 530 nm, respectively. Emissions for both GFP and RFP with
integration time of 3 s were recorded at 480–650 nm. Data are representative of two
independent experiments performed in triplicates. MK571 and JNJ-26854165 were used
as positive and negative controls, respectively. Compound induced FRET efficiencies
were normalized with the apo FRET to obtain the percent change in FRET. Results are
presented as mean ± SEM.

3.4 Discussion
Evidence have shown the development of MDR by cancer cells against various
anticancer agents as the chief obstacle to successful chemotherapy and this has been
notably linked to overexpressing of ABC drug efflux transporters. Most cancers that
overexpress MRP1 have poor prognosis and patients have low survival rates due to the
ability of MRP1 to efflux many first line chemotherapeutic drugs including vincristine,
doxorubicin and etoposide. For mostly hematological malignancies such as acute
myeloblastic leukemia and acute lymphoblastic leukemia, MRP1 overexpression has
been reported as the major determinant limiting the efficacy of chemotherapeutic agents.
[25, 30, 59]. Furthermore, studies have indicated that genetic variations in MRP1 such as
common polymorphisms may significantly increase drug resistance and disease
vulnerability [21, 60, 61]. Therefore the relevance of MRP1 in predicting patience
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outcome is a major concern in tumor management in clinical oncology. Clearly,
inhibition or downregulation of MRP1 is crucial for favorable therapeutic outcomes in
cancer treatment. Notwithstanding, various small molecular entities targeting MRP1
activity have been developed with generally organic anion transport inhibitors (e.g.
probenecid, sulfinpyrazone, indomethacin), tyrosine kinase inhibitors (TKIs) and some Pgp inhibitors among the leading MRP1 inhibitors. Although various in vitro evaluations
of these inhibitor compounds and their pharmacokinetic assessments with different
anticancer agents are still ongoing, motivation for these MRP1 inhibitors to go into
clinical trials has almost certainly faded due to setbacks (toxicity and zero clinical
benefits) experienced with P-gp inhibitors [62]. Nonetheless, new drug entities are
continually being discovered in the hopes of finding the ‘one’ MRP1 inhibitor.
Presently, there is growing interest in exploiting natural products as new entities
for drug design due to the less toxic and potent anticancer properties of natural
derivatives. In the present study, we investigated the ability of the natural product-derived
cucurbitacin-inspired estrone analogues, CIEAs, as potential MRP1 inhibitors. Firstly, we
demonstrated inhibition of MRP1 by these analogue compounds using a high content
fluorescence-based transport activity screening assay already developed and validated in
our lab. The MRP1 substrates, doxorubicin and calcein red orange were used as
fluorescent reporters for detection of MRP1 efflux inhibition by the CIEA compounds in
MRP1-overexpressing H69AR cell line. Performing two independent screenings on 81
CIEA compound library, the assay discovered 5 compounds as possible inhibitors of
MRP1 against doxorubicin efflux and 3 compounds against calcein red orange efflux.
Two compounds, HL 15 and HL 21 were detected as inhibitors for both doxorubicin and
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calcein red orange MRP1-mediated efflux suggesting that these two compounds may
have common overlapping binding sites for both MRP1 fluorescent substrates. This result
is also consistent with several biochemical and structural studies demonstrating MRP1’s
ability to recognize a broad spectrum of substrates as a result of its multiple distinct
substrate binding sites [63]. The assay yielded average Z’-factors of 0.50 and 0.59 for
doxorubicin and calcein red orange respectively which prove the fitness and effectiveness
of the high content screening assay for detecting cell-permeable, non-toxic and potent
inhibitors in live cells.
Subsequently, to understand the mechanism of the CIEA compounds on MRP1mediated MDR attenuation, and also confirm the high content screening results, we
performed drug accumulation studies. Our results indeed showed that the compounds
inhibit MRP1 efflux activity by increasing the intracellular concentrations of doxorubicin
and calcein red orange in MRP1-overexpressing H69AR cells (Figure 3.3A and 3.3B).
Visualization of MRP1-mediated efflux of doxorubicin in live cells using confocal
microscopy also validated the inhibitory action of the CIEAs on MRP1 function.
The ability of an MRP1 inhibitor to reverse multidrug resistance in cancer cells
could be very valuable in combinatorial treatment of tumors with especially high MRP1
expression levels. In the present study, we were interested to know if the CIEA
compounds were able to reverse MRP1-mediated resistance of common
chemotherapeutic drugs, vincristine and SN38. However, to prevent the cytotoxic action
of the CIEA compounds on the reversal outcome, we first obtained a dose-dependent
response of the CIEA compounds on the selected cell line. We then selected the noncytotoxic compound concentrations for the reversal studies. Three of the CIEA
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compounds significantly decreased resistance of H69AR cells towards vincristine. The
compounds, HL 15, HL 21 and HL 38 reduced the IC 50 value of the resistant H69AR
cells towards vincristine from 23.4 to 16.7, 15.5 and 18.1 nM, respectively. Moreover,
HL 53 did not show any sensitization of H6AR cells towards vincristine. On the other
hand, all 4 compounds, HL 15, HL 21, HL 38 and HL 53 reversed resistance of H69AR
towards SN38 by reducing IC50 value of H69AR resistant cells from 736.4 to 216.2,
631.7, 278.3 and 357.0 nM respectively. Among the 4 compounds, HL 15 was the most
potent in reversing resistance of H69AR towards both vincristine and SN38.
Interestingly, HL 21 was very effective in decreasing resistance of H69AR against
vincristine but was only modest in sensitizing H69AR cells to SN38. The results suggest
that substrate selective inhibition of MRP1 by the CIEA compounds may be crucial in
considering them for combinatorial therapy with chemotherapeutic agents for MDR
reversal. However, to provide a convincing evidence for the purpose stated, it is
necessary to investigate their chemosensitization effect in vivo. In addition, it is worth to
mention that, the reversal studies of these compounds be replicated with different
chemotherapeutic agents or different MRP1 resistant cell lines to deeply elucidate their
MDR reversal mechanisms. Further reversal studies could also be performed on other
ABC transporter MDR cell lines to ascertain whether the CIEA compounds reversal
capabilities are exclusive to MRP1.
The circumvention of MDR mediated by ABC transporters may be as a result
from down-regulation at the protein level. We tested this hypothesis by performing
Western blotting assay. Our results indicated that, the CIEA compounds have no effect
on MRP1 protein expression. The results may also suggest that the mechanisms of
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inhibition and reversal of MRP1 MDR by the CIEA compounds are independent of
MRP1 protein down-regulation. This could also mean the possibility of the CIEA
compounds to inhibit MRP1 activity may be dependent on other protein markers and/or
cross talk with other cell signaling pathways, which may directly or indirectly affect the
function of MRP1. To better elucidate their mechanism of action, time and
concentration-dependent studies should be conducted and also various signaling
pathways probed especially those involved in the EGFR route since this receptor is the
main pharmacological target of the CIEA compounds.
To confirm our belief that the CIEA compounds are MRP1 inhibitors and also
understand their binding interaction with MRP1 protein, we conducted molecular
docking studies. The results predicted that the CIEA compounds have better binding
affinities towards MRP1 protein than the known MRP1 inhibitor, MK571. To confirm the
binding affinities of the CIEA compounds as predicted by the molecular docking studies
and also investigate the ability of the compounds to directly interact and induced
conformational changes in MRP1 protein structure, we proceeded to use a two-color
MRP1 biosensor engineered in our lab coupled with steady-state fluorescence
spectroscopy. This biosensor has been used to screen a library of 40-novel clinical
anticancer drugs of which 10 of these drugs possibly interacted with MRP1 as substrates
[56]. Our FRET-based fluorescence spectroscopy results confirmed that the CIEA
compounds directly interact with MRP1 protein which strengthens our conviction that
the identified compounds are inhibitors of MRP1.
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3.5 Conclusion
In summary, our study demonstrated the competence of the high content
screening assay in determining novel inhibitors against MRP1 from a library of
cucurbitacin inspired estrone analogues (CIEAs). The study was able to investigate CIEA
compounds as potential MRP1 inhibitors. Functional studies with MRP1 confirmed that
the CIEA compounds inhibit the function of MRP1 by increasing the accumulation of
two MRP1 substrates. We also demonstrated the potential of these CIEA compounds to
re-sensitize MRP1 overexpressing cells to anticancer drugs, which is of great benefit to
overcome MDR in clinical cancer treatment. Lastly, we also showed that the identified
MRP1 inhibitor compounds have direct interaction with MRP1 protein.
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Chapter 4
General Conclusions and Recommendations
In general, we have demonstrated the potential of a novel compound series, CIEA
as inhibitors for P-gp and MRP1 mediated multidrug resistance. Using a high content
fluorescence-based transport activity assay, we were able to identify hit compounds
which were then further validated using established ABC transporter functional assays.
The hit compounds were also investigated for their reversal effect on multidrug resistant
cell lines towards selected anticancer agents. Protein expression studies were conducted
to evaluate the activity of the hit compounds on P-gp and MRP1 protein expression.
Finally, in silico molecular docking and FRET-based spectroscopic studies were used to
investigate direct interaction of the hit compounds with P-gp or MRP1 proteins.
In the first study, the high content fluorescence-based screening identified 8 CIEA
compounds as positive hits for P-gp inhibition. In addition all the hit compounds
displayed strong inhibition (in comparison to verapamil) of P-gp in flow cytometrybased calcein efflux and confocal microscopy -based doxorubicin localization assays.
The hit compounds also demonstrated various degrees of reversal of resistance and
selectivity towards vincristine, paclitaxel and etoposide in P-gp overexpressing multidrug
resistant HEK293/P-gp cells. However, all the compounds were very effective in
sensitizing MDR P-gp cells to etoposide. Moreover, protein expression studies revealed
that the compounds did not alter P-gp expression levels. Thus, the mechanism of P-gp
inhibition by the CIEA has no suppression on P-gp protein expression. Molecular
docking studies predicted that all the compounds have better binding affinities towards
the drug binding pocket of P-gp compared with verapamil, however, HL 20 was very
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potent in binding to the P-gp domain. Finally, we were able to confirm that the CIEA
compounds are potential ligands of P-gp. We came to the conclusion that the CIEA
compounds hold promise for use as agents for inhibiting P-gp mediated multidrug
resistance.
In the second study, the high content screening discovered 5 compounds as hits
for MRP1-mediated doxorubicin efflux inhibition and 3 compounds as inhibitors of
calcein red orange efflux. Two of the compounds (HL 15 and HL 21) identified as calcein
red orange inhibitors were also identified to inhibit doxorubicin efflux. The hit
compounds that were selected for further studies significantly increased the accumulation
of MRP1 substrates, doxorubicin and calcein red orange in functional characterization
studies. Drug sensitivity studies also showed selective sensitization of MRP1
overexpressing H69AR cells by the CIEA compounds towards the anticancer drugs,
vincristine and SN38, however, HL 15 demonstrated effective sensitization towards both
anticancer agents. Similarly as observed in P-gp, the CIEA compounds did not have any
effect on MRP1 protein expression. In silico molecular docking and fluorescence
spectroscopic studies confirmed inhibitor compounds interaction with MRP1 protein.
It is thought that, this study is the first of its kind to report the therapeutic
potential of CIEA with P-gp and MRP1. We anticipate that the results presented herein
will provide useful information on cucurbitacin-inspired estrone analogues as sources of
new drug discoveries for optimization as therapeutic strategies to overcome MDR in
cancer.
It is recommended that further studies are conducted to advance the CIEA compounds to
the clinical trials stages. Studies may include elucidating their mechanism of inhibition
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such as evaluating their effects on ATPase activity which is an important functional
requirement for P-gp and MRP1 mediated transport. In addition, transport studies using
membrane vesicles could provide a direct model to understand their mechanism of
inhibition. Finally, in vitro 3D tumor or vivo models may be used to assess the ultimate
pharmacokinetic impact of these compounds to establish their efficacy, safety and
toxicity levels. Depending on their pharmacokinetic profiles, the CIEA compound may
be optimized to advance their utilization in clinical studies.

